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A B S T R A C T
Background
TheWorld Health Organization recommends routine vitamin A supplementation during pregnancy or lactation in areas with endemic
vitamin A deficiency (where night blindness occurs), based on the expectation that supplementation will improvematernal and newborn
outcomes including mortality, morbidity and prevention of anaemia or infection.
Objectives
To review the effects of supplementation of vitamin A, or one of its derivatives, during pregnancy, alone or in combination with other
vitamins and micronutrients, on maternal and newborn clinical outcomes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 March 2015) and reference lists of retrieved studies.
Selection criteria
All randomised or quasi-randomised trials, including cluster-randomised trials, evaluating the effect of vitamin A supplementation in
pregnant women.
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.
Main results
We reviewed 106 reports of 35 trials, published between 1931 and 2015. We included 19 trials including over 310,000 women,
excluded 15 trials and one is ongoing. Overall, seven trials were judged to be of low risk of bias, three were high risk of bias and for
nine it was unclear.
1) Vitamin A alone versus placebo or no treatment
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Overall, when trial results are pooled, vitamin A supplementation does not affect the risk of maternal mortality (risk ratio (RR) 0.88,
95% confidence interval (CI) 0.65 to 1.20; four trials Ghana, Nepal, Bangladesh, UK, high quality evidence), perinatal mortality (RR
1.01, 95% CI 0.95 to 1.07; one study, high quality evidence), neonatal mortality, stillbirth, neonatal anaemia, preterm birth (RR 0.98,
95% CI 0.94 to 1.01, five studies, high quality evidence), or the risk of having a low birthweight baby.
Vitamin A supplementation reduces the risk of maternal night blindness (RR 0.79, 95% CI 0.64 to 0.98; two trials). There is evidence
that vitamin A supplements may reduce maternal clinical infection (RR 0.45, 95% CI 0.20 to 0.99, five trials; South Africa, Nepal,
Indonesia, Tanzania, UK, low quality evidence) and maternal anaemia (RR 0.64, 95% CI 0.43 to 0.94; three studies, moderate quality
evidence).
2) Vitamin A alone versus micronutrient supplements without vitamin A
Vitamin A alone compared to micronutrient supplements without vitamin A does not decrease maternal clinical infection (RR 0.99,
95% CI 0.83 to 1.18, two trials, 591 women). No other primary or secondary outcomes were reported
3) Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Vitamin A supplementation (with other micronutrients) does not decrease perinatal mortality (RR 0.51, 95% CI 0.10 to 2.69; one
study, low quality evidence), maternal anaemia (RR 0.86, 95% CI 0.68 to 1.09; three studies, low quality evidence), maternal clinical
infection (RR 0.95, 95% CI 0.80 to 1.13; I² = 45%, two studies, low quality evidence) or preterm birth (RR 0.39, 95% CI 0.08 to
1.93; one study, low quality evidence).
In HIV-positive women vitamin A supplementation given with other micronutrients was associated with fewer low birthweight babies
(< 2.5 kg) in the supplemented group in one study (RR 0.67, 95% CI 0.47 to 0.96; one study, 594 women).
Authors’ conclusions
The pooled results of three large trials in Nepal, Ghana and Bangladesh (with over 153,500 women) do not currently suggest a role
for antenatal vitamin A supplementation to reduce maternal or perinatal mortality. However, the populations studied were probably
different with regard to baseline vitamin A status and there were problems with follow-up of women. There is good evidence that
antenatal vitamin A supplementation reduces maternal night blindness, maternal anaemia for women who live in areas where vitamin
A deficiency is common or who are HIV-positive. In addition the available evidence suggests a reduction in maternal infection, but
these data are not of a high quality.
P L A I N L A N G U A G E S U M M A R Y
Vitamin A supplementation during pregnancy for maternal and newborn health outcomes
What is the issue?
Vitamin A is a fat-soluble vitamin found in liver, kidney, eggs, and dairy produce. Low dietary fat intake or intestinal infections may
interfere with the absorption of vitamin A. Natural retinoids are required for a wide range of biological processes including vision,
immune function, bone metabolism and blood production. In pregnancy, extra vitamin A may be required. Currently, the World
Health Organization (WHO) and other international agencies recommend routine vitamin A supplementation during pregnancy or
at any time during lactation in areas with endemic vitamin A deficiency (where night blindness occurs).
Why is this important?
It has been suggested that a low intake of vitamin A may be associated with complications in pregnancy such as death of the mother
or baby, increased infections for the mother or baby, low iron level for the mother or baby or having a baby with any of the following
complications: early delivery, low birthweight or a congential abnormality.
What evidence did we find?
This review included 19 studies involving over 310,000 women. Seven trials were conducted in Africa, six in Indonesia, two in
Bangladesh, and one each in Nepal, China, India, UK and USA. Most of the trials were conducted in populations considered to be
vitamin A deficient (except USA and UK). The overall risk of bias was low to unclear in most of the trials, and the body of evidence
was moderate to high quality. The findings indicate that routine supplementation with vitamin A (either alone or in combination with
other supplements) during pregnancy did not reduce mother or newborn baby deaths. There is good evidence that antenatal vitamin
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A supplementation does reduce maternal anaemia in women who live in areas where vitamin A deficiency is common or who are HIV-
positive. The trials published so far did not report any side effects or adverse events. The available evidence suggests a reduction in
maternal infection but these data are not of a high quality and further trials would be needed to confirm or refute this.
What does this mean?
Taking vitamin A supplements during pregnancy does not help to prevent maternal deaths (related to pregnancy) or perinatal or
newborn baby deaths. Taking vitamin A supplements during pregnancy does not help to prevent other problems that can occur such as
stillbirth, preterm birth, low birthweight of babies or newborn babies with anaemia. However, the risk of maternal anaemia, maternal
infection and maternal night blindness is reduced.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin A alone versus placebo or no treatment
Patient or population: Pregnant women
Settings: Areas with endemic vitamin A deficiency (inadequate intake)/areas with adequate intake as defined by the WHO global database on vitamin A deficiency
Intervention: Vitamin A alone versus placebo or no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo or no
treatment
Riskwith vitamin A alone
Maternal mortality Study population RR 0.88
(0.65 to 1.20)
154,039
(4 RCTs)
⊕⊕⊕⊕
HIGH 1
Inverse variance.
5 per 1000 5 per 1000
(4 to 7)
Perinatal mortality Study population RR 1.01
(0.95 to 1.07)
76,176
(1 RCT)
⊕⊕⊕⊕
HIGH
Inverse variance.
54 per 1000 54 per 1000
(51 to 57)
Maternal anaemia Study population RR 0.64
(0.43 to 0.94)
15,649
(3 RCTs)
⊕⊕⊕©
MODERATE 2
Inverse variance.
191 per 1000 122 per 1000
(82 to 180)
Maternal clinical infection Study population RR 0.45
(0.20 to 0.99)
17,313
(5 RCTs)
⊕⊕©©
LOW 23
Inverse variance.
18 per 1000 8 per 1000
(4 to 18)
Preterm birth Study population RR 0.98
(0.94 to 1.01)
48,007
(5 RCTs)
⊕⊕⊕⊕
HIGH
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249 per 1000 244 per 1000
(234 to 251)
Moderate
190 per 1000 186 per 1000
(178 to 192)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 The authors considered that the pooled effect estimate was not biased by the design of the studies or their analysis of data. Following
correspondence received from the trialists for Kirkwood 2010, the loss to follow-up for this study was 8%: the data from this study
are not at risk of attrition bias.
2 Statistical Heterogeneity (I² >60%).
3 Most studies contributing data had design limitations.
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B A C K G R O U N D
Description of the condition
Vitamin A general
Vitamin A is a fat-soluble vitamin that is derived from two sources:
preformed retinoids and provitamin carotenoids. Retinoids, such
as retinal and retinoic acid, are found in animal sources like liver,
kidney, eggs, and dairy produce. Carotenoids like beta-carotene
are found in plants such as dark or yellow vegetables and carrots.
Carotenoids can be converted to vitamin A in the liver where
vitamin A is stored. Absorption from plant sources is thought to
be low and animal sources (i.e. including dairy products) may be
needed to achieve adequate levels (Borel 2005; Tang 2005).
The digestion and absorption of vitamin A is closely associated
with lipid absorption. Factors such as low dietary fat intake or
intestinal infections may interfere with the absorption of vitamin
A (Mahalanabis 1979; Sivakumar 1972).
Natural retinoids are present in all living organisms, either as pre-
formed vitamin A or as carotenoids, and are required for a vast
number of biological processes including vision, gene transcrip-
tion, immune function, bone metabolism, haematopoiesis, skin
health and antioxidant activity (Combs 2008; McGuire 2007).
Sufficient stores (in the liver) may be able to maintain a person’s
requirement for months (FAO and WHO 2002).
In humans, vitamin A has three active forms (retinal, retinol and
retinoic acid), and a storage form (retinyl ester). The absorp-
tion of vitamin A depends on the amount of lipids ingested in
the diet, with lipids increasing uptake of beta-carotene and vita-
min A (Lidén 2006). Beta-carotene can be cleaved into retinoids
in the liver and the intestines by enzymes known as carotenoid
oxygenases, via two pathways - central or eccentric cleavage.
Central cleavage uses beta-carotene-15,15’-monooxygenase (EC
1.14.99.36), whereby beta-carotene is cleaved at its central 15,15’-
double bond to yield two retinal molecules, which are then con-
verted to two molecules of retinol (vitamin A). Eccentric (or asym-
metric) cleavage splits beta-carotene at double bonds other than
the central one, yielding beta-apocarotenals of different chain
lengths and carotenoic acids, which can then be converted to
one molecule of retinol. Under normal physiological conditions,
central cleavage is the predominant pathway (Lidén 2006; Moffa
1970; Von Lintig 2000).
Circulating vitamin A is transported in plasma in a 1:1 complex
with retinol-binding protein (RBP). RBP is bound to thyroxine
binding pre-albumin (TBPA) and this complex functions as a vi-
tamin A transport system. Binding is specific for vitamin A and
RBP is the only carrier of retinol in plasma.
The retina and other vitamin A dependent tissues have specific
binding sites forRBP and vitaminA.RBP is reduced in proteinuria
whichmay pose a serious threat for transport of retinol to tissues. In
conditions like kwashiorkor (protein malnutrition), levels of RBP
correct with improved protein nutrition even without vitamin A
supplements. RBP is also reduced in zinc deficiency states.
Diseases and conditions that impair the conversion of carotene
to vitamin A or reduce the levels of RBP can contribute to the
development of vitamin A deficiency as RBP is the main transport
protein for vitamin A.
Vitamin A in pregnancy and the newborn
In pregnancy, some extra vitamin A is required for growth and
tissuemaintenance in the fetus, for providing fetal reserves, and for
maternal metabolism. Pregnant women have a basal requirement
of 370 mcg/d (microgram/day), maximum dose of 3000 mcg/d
and recommended daily allowance (RDA) of 770 mcg/d (FNB
2001; Stipanuk 2006; WHO 1995). In the non-pregnant woman
(or pre-pregnancy), the daily basal requirement is estimated to be
300 mcg/d with a RDA of 700 mcg/d (Stipanuk 2006; WHO
1995). Generally, it is considered that liver stores are sufficient to
cover these extra needs in non-vitamin A deficient populations.
There are potentially adverse effects associatedwith vitaminA sup-
plementation during pregnancy. In the first 60 days post-concep-
tion, retinol is thought to be teratogenic (Rothman 1995; WHO
1998). A relationship has been suggested between the incidence of
birth defects and high vitamin A intakes during pregnancy, with
an apparent threshold of near 10,000 international units (IU) per
day (Mills 1997; Rothman 1995). Increased maternal levels of
preformed vitamin A (retinoic acid) have been shown to be as-
sociated with miscarriage and with malformations involving the
central nervous and cardiac systems (Miller 1998; WHO 1998).
A World Health Organization (WHO) expert group consultation
concluded that daily doses of up to 10,000 IU (equivalent to 3000
mcg retinol) or 25,000 IU weekly after day 60 are probably safe,
especially in areas where vitamin A deficiency is thought to be
common (WHO 1998).
The UK National Institute for Health and Clinical Excellence
(NICE) guidelines advise that, owing to potential teratogenic ef-
fects, women in developed (non vitamin A deficiency) countries
should avoid taking vitamin A supplements and liver; in other
words, avoiding the intake of vitamin A above 700 mcg per day
(NCCWCH 2008).
During pregnancy, vitamin A is transferred to the fetus via the
placenta by active mechanisms that maintain the transfer over a
wide range of maternal dietary intake. In contrast, during lacta-
tion, vitamin A concentration in breast milk is more sensitive to
variations in maternal intake (Ross 1994). The estimated require-
ment for vitamin A in newborn infants up to six months of age is
180 mcg/d, with a safe intake level of 350 mcg/d.
Newborn infants normally have a low level of vitamin A in the
liver and they increase these stores in the first few months if the
breast milk has adequate levels. Preterm infants have reduced hep-
atic (liver) stores and lower levels of retinol binding protein (the
vitamin A carrier protein) in the plasma compared to babies born
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at term. Insufficient intake and reduced absorption by the imma-
ture gut may exacerbate deficiencies in preterm infants (Darlow
2007).
Measurement of vitamin A status
In the literature on vitamin A, authors have used a variety of differ-
ent indicators and units of measurement. This can be confusing.
In general, the following conversions can be used:
1. serum retinol 1 µmol/L = 28.6 µg/dL or 10 µg/dL = 100
µg/L = 0.35 µmol/L;
2. for supplement doses 1 µg retinol equivalent = 0.00349
µmol retinol = 3.33 IU vitamin A or, expressed differently, 1 IU
vitamin A = 0.3 µg retinol and 0.00105 µmol retinol.
For this review we will endeavour to report whenever known the
supplemented dose of vitamin A given in or converted to IU.
There are problems associated with the biochemical assessment
of vitamin A deficiency. Serum retinol, because of homeostatic
control exerted by the liver, is not a good general indicator of
vitamin A status.
Serum retinol levels reflect liver vitaminA stores onlywhen they are
severely depleted (less than 0.07 µmol/g liver) or extremely high
(more than 1.05 µmol/g liver). Between these extremes, serum
retinol is homeostatically controlled and thus not always correlated
with vitamin A intake or clinical signs of deficiency. Consequently,
serum retinol is not useful in assessing the vitamin A status of
individuals. Rather, the distribution of serum retinol values in
populations, and the prevalence of individuals with serum retinol
values below a given cut off, can provide important information on
the vitamin A status of a population and can indicate the severity
of vitamin A deficiency as a public health problem (Sommer
1995; WHO 1996). Serum retinol concentrations of 1.05, 0.70
and 0.35 µmol/L have been used in the published literature to
indicate inadequate, moderately inadequate and very inadequate
liver stores respectively (Underwood 1990).
Clinical manifestations of vitamin A deficiency
Symptoms of vitamin A deficiency include a variety of eye symp-
toms, such as night blindness, xerophthalmia (dry eyes, failure to
produce tears), keratomalacia (drying and clouding of the cornea
with ulceration), Bitot spots (keratin debris in the conjunctiva) and
photophobia. Follicular hyperkeratosis (excessive development of
keratin in hair follicles), which is also seen with general malnu-
trition, can be a manifestation of vitamin A deficiency. Ocular
changes can be documented quantitatively using a dark adapta-
tion test (e.g. the papillary threshold test - PTT) or using elec-
troretinography. Often change in night blindness is assessed via
a simple before (the intervention) and after (the intervention or
treatment) questionnaire. In babies born prematurely, symptoms
of vitamin A deficiency include bronchopulmonary dysplasia (a
form of chronic lung disease).
Night blindness is thought to be one of the first signs of vitamin
A deficiency, followed by a diminished ability to fight infections
especially respiratory and gastroenteric infections (Sommer 1982;
Stephens 1996).
Description of the intervention
Vitamin A supplementation
In non-pregnant populations, vitamin A supplementation to-
gether with iron has led to improved haemoglobin (Hb) levels in
a number of studies (Bloem 1990; Mejia 1988). Fortification of
food stuffs with vitamin A in Guatemala (sugar) and Indonesia
(monosodium glutamate) was reported to improve ferritin levels
(Mejia 1982) andHb concentration (Muhilal 1988). Intervention
studies in Indonesian girls showed that a multivitamin regimen
including vitamin A together with iron supplementation was more
effective than iron alone or a multivitamin without vitamin A for
improving ferritin levels (Angeles-Agdeppa 1997).
Trials of vitamin A supplementation to reduce the risk of mother-
to-child transmission of HIV infection in HIV-positive pregnant
women and the effect of vitamin A supplementation in the post-
natal period are reviewed in separate Cochrane reviews (Oliveira
2010; Wiysonge 2011).
An early study suggested that vitamin A supplementation at time
of delivery (oral not intramuscular) may result in an increase of
vitamin A in colostrum (Ajans 1965).
A number of studies have assessed the role of vitamin A sup-
plementation on infectious mortality and morbidity in children
in developing countries. These have been systematically reviewed
(Glasziou 1993). Vitamin A supplementation was associated with
a 30% reduction of death with a larger reduction (66%) in chil-
dren hospitalised with measles. Similar results were found in an-
other review (Fawzi 1993).
How the intervention might work
Vitamin A deficiency
Formany countries there are still no accurate data on vitaminA sta-
tus of pregnant women. However, in areas where night blindness is
common, vitamin A deficiency is often assumed to be widespread.
Vitamin A deficiency is thought to be a significant problem in
many developing countries in Africa, South and South-East Asia
and areas of Latin America and theWestern Pacific (WHO 1995).
Reports of population deficiency are often based on the assessment
of night blindness and other eye symptoms among pre-school chil-
dren in various countries. The most obvious deficiency signs are
dryness of the conjunctiva and the cornea (xerophthalmia), which
can lead to permanent eye damage (McGuire 2007).
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It is also known that a diet devoid of vitamin A results in decreased
Hb levels (Hodges 1978). Vitamin A deficiency has been found to
co-exist with iron deficiency in a number of developing countries
(Karyadi 1996). Several international studies have documented
a positive association between serum retinol and Hb concentra-
tion in children (Mejia 1977; Wolde-Gabriel 1993), and pregnant
women (Suharno 1992). Anaemia in pregnancy has been associ-
ated with vitamin A deficiency (Van den Broek 1998; Van den
Broek 2000).
Vitamin A is involved in the growth and differentiation of epithe-
lial tissues and also has a role in immunoprotection (Thurnham
1989; Tomkins 1989). Infections most closely associated with vi-
tamin A deficiency are those in which structure or function of
the epithelium may be impaired such as measles, diarrhoea and
respiratory disease. Febrile infections are associated with reduced
serum levels of retinol binding protein and retinol. This is thought
to be an acute phase reaction (Cox 2006; Long 2007). On the
other hand, infection and inflammation can depress serum retinol
values, as can other micronutrient deficiencies (Thurnham 1989;
Tomkins 1989).
Other changes associated with vitamin A deficiency include im-
paired immunity, and squamous metaplasia of the epithelium lin-
ing the upper respiratory passages and urinary bladder leading to
a keratinised epithelium. In relation to dentistry, a deficiency in
vitamin A leads to enamel hypoplasia (Underwood 1994; WHO
1995).
Finally, there is some evidence that dietary carotenoids have pro-
tective function against some human cancers (Rousseau 1992).
Why it is important to do this review
Vitamin A supplementation in pregnancy
Currently, theWHO recommends routine vitamin A supplemen-
tation during pregnancy or at any time during lactation in areas
with endemic vitamin A deficiency (where night blindness occurs)
(WHO 1998). The principal forms used as nutritional supple-
ments are vitamin A palmitate (retinyl palmitate) and vitamin A
acetate (retinyl acetate), but carotenoids (most commonly beta-
carotene) and retinoids (retinol, retinal, retinoic acid) can also be
used as nutritional supplements (DRI 2001).
VitaminA supplementationduringpregnancy and (extended into)
the postnatal period may be expected to affect outcomes such as
maternal and newborn mortality, maternal and newborn anaemia
or infection or other morbidity and there is also a need to docu-
ment if supplementation with vitamin A has been associated with
any harmful effects. A number of new trials have been published
since the first review on vitamin A supplementation for pregnancy
outcomes in 2002 (Van den Broek 2002) and it is therefore im-
portant to review all current evidence regarding vitamin A sup-
plementation to inform and review the existing recommendations
for practice.
O B J E C T I V E S
To review the effectiveness of the supplementation of vitamin A
or one of its derivatives during pregnancy, alone or in combina-
tion with other vitamins and minerals, on maternal and newborn
clinical and laboratory outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised or quasi-randomised trials, including cluster-ran-
domised trials, evaluating the effect of vitamin A supplementation
in pregnant women.
We excluded trials where vitamin A is given only in the postnatal
period but included trials where vitamin A was commenced pre-
pregnancy or during pregnancy and continued into the postnatal
period.
The outcome ’HIV transmission’ was not considered in this re-
view as it is covered in another Cochrane review (Wiysonge 2011),
but we included data from randomised controlled trials aimed at
preventing vertical transmission if they meet our criteria for in-
clusion and report obstetric and infant outcomes relevant to our
review. In addition, this current review is different from Haider
2008 which reviews the effects of multi-micronutrient supple-
ments which could include vitamin A but does not assess the effect
of vitamin A alone.
Types of participants
Pregnant women receiving vitamin A supplementation either in
areas with endemic vitamin A deficiency (inadequate intake) or in
areas with adequate intake as defined by theWHO global database
on vitamin A deficiency.
Types of interventions
Vitamin A (or one of its derivatives) supplementation, alone or
in combination with other supplements compared with a control
group. The control group could be placebo, no treatment or an-
other intervention (for example, iron).
Researchers report vitamin A measurements in different units. Ac-
cordingly, we used the following tables for conversions: Table 1;
Table 2.
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Comparisons included: vitamin A (or derivative):
1. alone versus placebo or no treatment;
2. alone versus micronutrient supplements (may include iron
or/and folic acid) without vitamin A;
3. in combination with other micronutrients versus
micronutrient supplements without vitamin A.
Types of outcome measures
The outcomes of this review are maternal and perinatal clinical
outcomes.
This review focuses on effects on maternal and newborn mortality
and morbidity such as anaemia and infection (but not on HIV
which is reviewed elsewhere).
We sought information on the following outcomes for this review.
Primary outcomes
1. Maternal mortality (defined as the death of a woman while
pregnant or within 42 days of termination of pregnancy,
irrespective of the duration and site of the pregnancy, from any
cause related to, or aggravated by, the pregnancy or its
management but not from accidental or incidental causes
(ICD-10 2007)).
2. Perinatal mortality (defined as number of stillbirths and
deaths in the first week of life per 1000 live births (HAP 2008;
PNM 2005)).
Secondary outcomes
1. Neonatal mortality (defined as the number of deaths during
the first 28 completed days of life per 1000 live births in a given
year or period (PNM 2005)).
2. Stillbirths (as defined by the trial author).
3. Maternal anaemia (haemoglobin (Hb) less than 11.0 g/dL).
4. Maternal clinical infection (as defined by the investigator).
5. Maternal night blindness (reported or with demonstrable
ocular lesion or abnormal adaptation test).
6. Preterm birth (less than 37+0 weeks gestational age).
7. Neonatal anaemia (as defined by investigator).
8. Neonatal clinical infection (as defined by investigator).
9. Congenital malformations (any reported).
10. Low birthweight (less than 2.5 kg).
Where outcomes were not given according to the definitions spec-
ified above, we have noted this in the ’Characteristics of included
studies’ tables and included outcomes in the analyses wherever
possible.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s
Trials Register by contacting the Trials Search Co-ordinator (30
March 2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see van
den Broek 2010.
For this update, the following methods were used for assessing the
23 reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreement through discussion or, if required, we
consulted the third review author.
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors extracted the data using the agreed form.We resolved
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discrepancies through discussion or, if required, we consulted the
third review author. Data were entered into Review Manager soft-
ware (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
planned to contact authors of the original reports to provide fur-
ther details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in theCochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Any disagreement
was resolved by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
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(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we planned to
assess the likely magnitude and direction of the bias and whether
we considered it is likely to impact on the findings. We explored
the impact of the level of bias through undertaking sensitivity
analyses - see Sensitivity analysis.
Assessment of the quality of the evidence using
GRADE
For this update we assessed the quality of the evidence using the
GRADE approach as outlined in the GRADE handbook in order
to determine the quality of the body of evidence relating to the
following outcomes
1. Maternal mortality
2. Perinatal mortality
3. Preterm birth
4. Maternal anaemia
5. Maternal infection
for the following main comparisons: vitamin A (or derivative):
1. alone versus placebo or no treatment;
2. in combination with other micronutrients versus
micronutrient supplements without vitamin A.
We used GRADEproGuidelineDevelopmentTool to import data
fromReviewManager 5.3 (RevMan 2014) in order to create ’Sum-
mary of findings’ tables. A summary of the intervention effect and
a measure of quality for each of the above outcomes was produced
using theGRADE approach. TheGRADE approach uses five con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of the body
of evidence for each outcome. The evidence can be downgraded
from ’high quality’ by one level for serious (or by two levels for very
serious) limitations, depending on assessments for risk of bias, in-
directness of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
No continuous data was analysed in this update. If appropriate,
in future updates, we will use the mean difference if outcomes
are measured in the same way between trials. We will use the
standardised mean difference to combine trials that measure the
same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
We included cluster-randomised trials in the updated review.
One study (West 2011) had reported the results using generalised
estimating equation linear regression model and generalised es-
timating equations binomial regression. These methods had ac-
counted for the clustering in the data. Hence, effect estimates and
standard errors were meta-analysed using the generic inverse-vari-
ance method in RevMan.
For other studies and outcomes we adjusted their standard error
using the methods described in the Handbook [Section 16.3.6]
using an estimate of the intra cluster correlation co-efficient (ICC)
derived from the trial.We synthesised the relevant information and
considered wether it was reasonable to combine the results from
both if therewas little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit was considered to be unlikely.
We also acknowledged heterogeneity in the randomisation unit
and performed a sensitivity analysis to investigate the effects of the
randomisation unit.
Other unit of analysis issues
Multiple-arms trials
Where a trial hadmultiple intervention armswe avoided ’doubling’
of participants by combining groups to create a single pair-wise
comparison if possible. Where this was not possible we split the
’shared’ groups into two or more groups with smaller sample size
and included two or more (reasonably independent) comparisons.
Dealing with missing data
For included studies, we noted levels of attrition. In future updates,
if more eligible studies are included, we will explore the impact
of including studies with high levels of missing data in the overall
assessment of treatment effect by using sensitivity analysis.
For all outcomes, analyses were carried out, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised to each group in the analyses. The denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either the Tau² was
greater than zero, or there was a low P value (less than 0.10) in
the Chi² test for heterogeneity. If we identified substantial het-
erogeneity (above 30%), we planned to explore it by pre-specified
subgroup analysis.
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Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary, if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average of the range
of possible treatment effects and we discussed the clinical impli-
cations of treatment effects differing between trials. If the average
treatment effect was not clinically meaningful, we did not com-
bine trials. If we used random-effects analyses, the results were
presented as the average treatment effect with 95% confidence in-
tervals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses and sensitivity analyses.We considered whether
an overall summarywasmeaningful, and if it was, we used random-
effects analysis to produce it.
Where possible, we carried out the following subgroup analyses.
1. Countries with high versus low infant mortality rates (high
infant mortality rate greater than or equal to 30/1000 live births
(IMCI- TAG 2008)).
2. Countries with high versus low maternal mortality rates
(high maternal mortality rate greater than 100 per 100,000 live
births (WHR 2005)).
3. High versus low prevalence of vitamin A deficiency (as
defined by WHO for the country or by the investigator).
4. Countries with a low versus high prevalence of HIV in the
general population (high-prevalence countries defined as
countries with national prevalence that exceeded 3% of the
general population (AIDS Report 2008)).
5. Dose: daily 10,000 IU versus other doses.
6. Regimen: daily versus weekly.
7. Duration of intervention: by number of weeks.
8. Trimester of pregnancy in which supplementation was
started (prepregnancy supplementation versus first trimester
versus second trimester versus third trimester).
We used only primary outcomes in subgroup analysis.
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2014). We reported the results of sub-
group analyses quoting the Chi² statistic and P value, and the in-
teraction test I² value.
Sensitivity analysis
We planned to carry out out sensitivity analyses to explore the
effect of trial quality assessed by concealment of allocation, high
attrition rates, or both, with poor quality studies being excluded
from the analyses in order to assess whether this makes any dif-
ference to the overall result. These sensitivity analyses were not
conducted in this update.
R E S U L T S
Description of studies
Results of the search
We reviewed 106 reports of 35 trials, published between 1931
and 2015. We included 19 trials including over 310,000 women,
excluded 15 trials and one is ongoing.
Included studies
For detailed characteristics of the included studies, see
Characteristics of included studies.
Study designs
Of the 19 included trials, three were cluster-randomised (
Kirkwood 2010; West 1999; West 2011), while the rest were
based on randomisationof individual women.Only two trialswere
quasi-randomised (Green 1931; Suprapto 2002).
Settings
Seven trials were conducted inAfrica: three inMalawi (Kumwenda
2002; Semba 2001; van den Broek 2006), one in South Africa
(Coutsoudis 1999), two in Ghana (Cox 2005; Kirkwood 2010),
and one in Tanzania (Fawzi 1998). Six of the included trials
were conducted in Indonesia (Dijkhuizen 2004; Hakimi 1999;
Muslimatun 2001; Suharno 1993; Suprapto 2002; Tanumihardjo
2002). Two trials were conducted in Bangladesh (Ahmad 2009;
West 2011). One trial was conducted in Nepal (West 1999), one
in China (Sun 2010) and one in India (Radhika 2003).
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Population
All trials were conducted in populations considered to be moder-
ately vitamin A deficient before the relevant trial was commenced
except one trial (West 1999) that was conducted inNepal in which
the population was considered to be severely deficient in vitamin
A (FAO and WHO 2002; FNB 2001; WHO 1996). Two trials
in the USA and UK were conducted in populations that were not
a considered vitamin A deficient (Ajans 1965; Green 1931).
Interventions/Controls
Ten trials used Vitamin A (or one of its derivatives) supple-
mentation alone compared with a control group (Ajans 1965;
Coutsoudis 1999; Cox 2005; Green 1931; Kirkwood 2010;
Kumwenda 2002;Radhika 2003; van denBroek 2006;West 1999;
West 2011).
Five trials used Vitamin A in combination with other supplements
compared to a control group (Dijkhuizen 2004; Muslimatun
2001; Semba 2001; Sun 2010; Suprapto 2002).
Four trials investigated both the use of Vitamin A (or one of its
derivatives) supplementation alone andVitaminA in combination
with other supplements compared with a control group (Fawzi
1998; Hakimi 1999; Suharno 1993;Tanumihardjo 2002).
The control group included either a placebo, no treatment or
another intervention (for example, iron).
Researchers reported vitamin A measurements in different units.
Included studies addressing primary outcomes
Maternal Mortality
Four trials reported maternal mortality as a primary outcome.
Women of reproductive age were given weekly vitamin A supple-
ments.
Green 1931 is a quasi-randomised trial conducted in the UK. Two
hundred and seventy-five women received the vitamin A prepa-
ration and 275 women did not, serving as controls . Vitamin A
preparation was given as 1 oz of the vitamin preparation radios-
toleum, an amount equivalent in vitamins A and D roughly to 30
oz of a good cod-liver oil, and should have been taken commenc-
ing one month prior to the calculated day of labour. The first 76
cases prior to June 1929 were given the preparation for only 14
days before delivery (daily). It was, however, continued for the first
seven days of the puerperium. Maternal mortality was one of the
outcomes assessed.
In the Nepal trial byWest 1999, more than 36,800 deliveries were
analysed as part of a cluster-randomised field trial conducted in
South-East Nepal among a total of 30 village development com-
munities, which are small subdistricts, each of which comprises
nine wards. A total of 270 wards were randomised to three groups
of 90 each, including 44,646 women of reproductive age receiving
a weekly single oral supplement of vitamin A (23 310 IU vitamin
A or 7000 mcg retinol equivalents) or beta carotene (42 mcg, or
7000 mcg retinol equivalent) or placebo. Pregnant women were
eligible to be included in the analysis if they had received sup-
plements for at least five months before conception. The primary
outcome of the trial was pregnancy-related and direct mortality
occurring up to 12 weeks postpartum and included injury-related
deaths.
The trial from Ghana, Kirkwood 2010, is the largest trial with
the inclusion of more than 207,000 pregnant women. This was
a cluster-randomised trial. All women aged 15 to 45 years living
in seven predominantly rural districts in Brong Ahafo Region in
Ghana who were capable of giving informed consent and who
planned to live in the trial area for at least three months were
eligible for enrolment. Implementation was phased by district.
The vitamin A capsule consisted of 25 000 IU (7500 µg) retinol
equivalents in soybeanoil in a dark red opaque soft gel. The placebo
capsule consisted of soybean oil only. The primary outcomes of
the trial were pregnancy-related mortality and to compare this
with the effect on overall all-cause female mortality. Secondary
outcomes were severe maternal morbidity and perinatal and infant
mortality. A secondary analysis (Hurt 2013) was conducted of the
Kirkwood 2010 trial to determine the effect of weekly vitamin A
supplementation on cause-specific mortality in women.
West 2011 conducted a double-blind cluster-randomised placebo-
controlled trial in 596 sectors in the rural northwestern district of
Gaibandha and Rangpur in Bangladesh between 2001 and 2007.
Married women (n = 125,257) underwent five-week surveillance
for pregnancy, ascertained by a history of amenorrhoea and con-
firmed by urine test. Blood samples were obtained from partici-
pants in 32 sectors (5%) for biochemical studies. A total of 59,666
women were eligible for inclusion in this study and were divided
into three intervention groups: 7000 ug of retinol equivalent as
retinyl palmitate, 42 mg of all-trans beta- carotene, or placebo.
One of the primary outcomes was all-cause mortality of women
related to pregnancy. Other outcomes included stillbirth and in-
fant mortality to 12 weeks (84 days) following the pregnancy out-
come and are described under neonatal outcomes.
Perinatal mortality
None of the included trials investigated perinatal mortality as a
primary outcome.
Included studies addressing secondary outcomes
Maternal anaemia
A total of nine trials specifically assessed the effect of vitamin A on
haemoglobin (Hb) levels. Vitamin A was given during the ante-
natal period in combination with other micronutrients, generally
iron and folic acid.
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There are five studies from Indonesia which assess effect of vitamin
A on Hb.
Suharno 1993 included 305 women from 20 rural villages inWest
Java, 16 to 24 weeks pregnant, with Hb concentrations between
8.0 and 10.9 g/dl. Women were assigned to one of four groups
to receive daily supplements: one group received vitamin A (2.4
mg retinol as retinyl palmitate which equates to about 8000 IU
vitaminA) and placebo iron tablets; the second group received iron
(60 mg elemental iron as ferrous sulphate) and placebo vitamin A;
the third group received both the vitamin A and iron supplements
(as described in groups one and two); and the fourth group received
placebos only.
In Tanumihardjo 2002, pregnant women in the second or early
third trimester were recruited from the suburban areas of Bogor
in West Java, Indonesia. Ages ranged from 18 to 37 years and
parity from 0 to four children. Women were randomly assigned
to the following four supplementation groups: placebo, 8.4 mol
(8000 IU) vitamin A as retinyl palmitate with an iron placebo,
1.07 mmol (60 mg) ferrous sulphate with a vitamin A placebo and
vitamin A plus iron. The daily supplementation was monitored
using a control card and check list by the volunteers who were
responsible for administration of the doses.
Suprapto 2002 was a quasi-randomised trial. It took place in the
rural area of Banyudono subdistrict, Boyolali regency, Central
Java province, Indonesia. All pregnant women who visited the
Banyudono health centres’ antenatal clinics from July to Novem-
ber 2000 were asked to participate in the study. All pregnant
women were numbered and listed. They were then allocated alter-
nately into groups according to their numbers. Group IF (n = 29)
received iron-folate tablets + 5 mg glucose (placebo); group IFR
(n = 22) received iron-folate tablets + 5 mg riboflavin; group IFA
(n = 29) received iron-folate tablets + 2.75 mg retinyl palmitate
(equal to 5000 IU vitamin A); and group IFRA (n = 23) received
iron-folate tablets + 5 mg riboflavin + 2.75 mg retinyl palmitate.
These were administered seven days a week for 60 days.
Muslimatun 2001 was carried out in the rural subdistrict of
Leuwiliang, West Java, Indonesia. Pregnant women were sup-
plemented once weekly from enrolment until delivery with two
tablets each containing 60 mg iron as ferrous sulphate and 250 mg
folic acid or with two tablets each containing 2400 retinol equiv-
alents (RE) vitamin A in addition to the same amount of ferrous
sulphate and folic acid.
In Dijkhuizen 2004, all women were recruited before 20 weeks’
gestational age from 13 adjacent villages in a rural area in Bogor
District, West Java, Indonesia. Each woman was supplemented
daily during pregnancy until delivery. All women received iron and
folic acid (30mg iron as ferrous fumarate/d and 0.4mgpteroylglu-
tamic acid/d). In addition, one group of women received -carotene
(4.5 mg as water-soluble granulate/d; -carotene group), one group
received zinc (30 mg zinc as sulphate/d; zinc group), one group
received -carotene plus zinc (4.5 mg -carotene and 30 mg zinc/d;
-carotene zinc group), and one group received only iron and folic
acid (control group).
There are two trials fromMalawi where the primary outcome was
effect of vitamin A on Hb.
The Semba 2001 trial was conducted in women attending a teach-
ing hospital antenatal clinic. Pregnant women were given daily
supplements of either vitamin A (3000 mcg retinol equivalent,
which equals 10,000 IU vitamin A), or placebo. All women re-
ceived daily iron (30 mg) and folate (400 mcg). In addition, all
women received two doses of Fansidar during pregnancy as pre-
sumptive treatment for malaria. Outcomes were measured at 38
weeks and included Hb concentration and erythropoietin. Iron
status was measured using serum ferritin and markers of inflam-
mation included C-reactive protein (CRP) and alpha-acid glyco-
protein. VitaminA status wasmeasured using serum retinol. Com-
pliance with supplements was assessed via monthly tablet counts.
The van den Broek 2006 trial included a representative group
of rural women attending antenatal clinic in southern Malawi.
Women received daily supplements of either vitamin A 10,000
IU or vitamin A 5000 IU, or a placebo. In addition, all women
received daily iron supplements (60 mg elemental iron as ferrous
sulphate with 0.25 mg folic acid). Thirty-two per cent of women
recruited were HIV-positive. Mean duration of supplementation
was 14 weeks. The three main outcome measures were Hb level,
prevalence of anaemia ((Hb) < 11.0 g/dL) and severe anaemia
((Hb) < 8.0 g/dL) after supplementation. Secondary outcomes
included vitamin A status, iron status and infection status.
One study from India and one study fromChina assessed the effect
of antenatal supplementation on Hb levels.
Radhika 2003 is a randomised clinical trial of red palm oil sup-
plementation and was conducted in pregnant women attending
the outpatient department of Niloufer Hospital, Hyderabad, In-
dia, between January 2001 and March 2002. The women in the
experimental group received red palm oil providing 2173 to 2307
µg of β-carotene per day with a dosage schedule of one sachet per
day (8 mL). The women in the control group received one sachet
of groundnut oil (8 mL). A detailed clinical anthropometric and
obstetric examination was conducted in all the women at baseline
and every two weeks up to 36 weeks and thereafter every week
until delivery. All the women received iron folate tablets (60 mg
of iron and 500 µg of folic acid) for 100 days and routine prenatal
care.
Sun 2010 is a double-blind randomised trial with a two-month
duration, conducted in the Shen County in a central rural area
of China. In this trial, 186 anaemic pregnant women with a Hb
concentration > 80 and < 110 g/L were allocated to four groups.
Group one (n = 47) was supplemented daily with 60 mg iron as
ferrous sulphate; Group two (n = 46) with 60 mg and 0.4 mg folic
acid; Group three (n = 46) with 60 mg iron, 2.0 mg retinol and
0.4 mg folic acid; and Group four (n = 47) was the placebo control
group.
Three studies trials were conducted in HIV-positive pregnant
women with the main intent of looking at the effect of vitamin A
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supplementation on mother to child transmission of HIV. These
trials also report on other outcomes relevant to this review and
are included. In the trial by van den Broek 2006 in rural Malawi,
32% of all recruited women were HIV-positive but this trial was
designed to assess the effect of vitamin A on Hb levels and HIV
transmission was not measured.
In Kumwenda 2002, the study population consisted of HIV-posi-
tive pregnant women of 18 to 28 weeks’ gestation who were seen at
the antenatal clinic of theQueenElizabethCentralHospital (Blan-
tyre, Malawi) fromNovember 1995 through December 1996. All
women received orally administered daily doses of iron (30 mg of
elemental iron) and folate (400 mg) from the time of study enrol-
ment until delivery. One-half of the women were randomised to
receive daily doses of orally administered vitamin A (3 mg retinol
equivalent (10,000 IU); the vitamin A group), from the time of
study enrolment until delivery.
One trial was conducted in the republic of South Africa:
Coutsoudis 1999 is a double-blind randomised trial conducted in
King Edward VIII Hospital and McCords Hospital, in Durban,
South Africa. HIV-positive women of 28 to 32 weeks’ gestation
were randomised to receive either placebo or a daily dose of 5000
IU retinyl palmitate and 30 mg beta-carotene during the third
trimester of pregnancy and 200,000 IU retinyl palmitate at deliv-
ery.
One study from Tanzania (Fawzi 1998), recruited pregnant
women between 12 and 27 weeks’ gestation who were HIV in-
fected and resident in Dar es Salaam. Women were assigned in
a two-by-two factorial design. One thousand and seventy-five
women received a daily oral dose of: vitamin A (30 mg beta-
carotene plus 5000 IU preformed vitamin A, n = 269); multivi-
tamins excluding vitamin A (20 mg B1, 20 mg B2, 25 mg B6,
100 mg niacin, 50 µg B12, 500 mg C, 30 mg E, and 0·8 mg folic
acid, n = 269); multivitamins including vitamin A (n = 270), all
formulated in two tablets; or two tablets of placebo (n = 267).
Eighty-five per cent of women took the single large dose of the
supplement or placebo at delivery; the other 15% were not given
this dose because they delivered at home or at another clinic.
Maternal Infection
For three trials themain outcome measure was maternal infection.
Ajans 1965 conducted a randomised controlled trail in the USA
in 44 parturient women who were allotted at random to one of
three groups after admission to the delivery suite of the Ameri-
can University Hospital. Group one was the control group that
included 18 women who were not given any form of vitamin A
therapy prepartum. Group two comprised 15 women who were
all given a single intramuscular injection of 600,000 lU of vitamin
A palmitate in oil at parturition. Group three was made up of 11
women who were given 600,000 lU of water-dispersible vitamin
A palmitate orally shortly before delivery. Four samples of 2 mL
to 3 mL of colostrum were also collected from each woman: one
antepartum sample and three postpartum samples, one on each
consecutive day of hospitalisation. The main outcome was levels
of maternal infection in breast milk.
Green 1931 described previously, also assessed maternal infection
as one of the main outcomes defined as puerperal fever > 38o C.
Hakimi 1999 describe the Zibuvita trial, a double-blind ran-
domised controlled trial conducted in Central Java, Indonesia.
One group received vitamin A 2400 retinol equivalent, the sec-
ond group received zinc 20 mg/day, the third group received both
vitamin A and zinc, while the fourth group received placebo. The
main objective was to assess puerperal pyrexia (body temperature
> 37.5 C) and puerperal sepsis (body temperature > 38.0 C) on at
least one day in the postpartum period. Of note, this study infor-
mation is from a draft of a publication which was not published
in any peer review journal. However, two follow-up studies using
this original trial data have been published (Prawirohartono 2011;
Prawirohartono 2013).
Six follow-up studies of five included trials (Cox 2005; Dijkhuizen
2004; Fawzi 1998; Sun 2010; West 2011) reported on maternal
infection as a secondary outcome.
Dijkhuizen 2001 measured maternal puerperal fever as an sec-
ondary outcome in a trial described previously, Dijkhuizen 2004.
Cox 2005 recruited primigravid pregnant women from antenatal
clinics at Nkoranza District Hospital and three rural health clinics
in Brong Ahafo region, Central Ghana. Women were randomised
to either capsules, which were given weekly and contained 10,000
IU of vitamin A as retinyl palmitate in groundnut oil, plus toco-
pherol as a preservative from enrolment until six weeks’ postpar-
tum, or groundnut oil and tocopherol only in the placebo capsules
from enrolment until six weeks’ postpartum.
A short two-month duration trial in China (Sun 2010) described
previously, assessed the effect of iron combined with retinol sup-
plements in an anaemic pregnant population. The proxymeasure-
ments of interleukin 2 (IL-2) level and lymphocyte proliferation
were assessed in an attempt to measure the impact on the maternal
immune system and as an indirect measure of the maternal ability
to combat infection.
Arsenault 2010 assessed a subgroup of the 1078 trial participants
in the study of HIV-positive women in Tanzania (Fawzi 1998) for
subclinical mastitis, defined as a ratio of the sodium to potassium
(Na:K) breastmilk concentration > 0.6. A total of 1642 breastmilk
samples were obtained by manual expression from 674 women
from delivery and every three months up to two years postpartum.
Olofin 2014 also assessed the incidence of malaria in this same
trial population (Fawzi 1998). Malaria was defined in two ways:
presumptive diagnosis based on a physicians’s or nurses’s clinical
judgement or periodic examination of blood smears for malaria
parasites.
Christian 2011 conducted a trial as a substudy of the West 2011
trial and assessed the risk of maternal bacterial vaginosis in the
study population. Thirty-three of the total 596 clusters were ran-
domly assigned to the three intervention groups (West 2011) and
women were examined for bacterial vaginosis by using self admin-
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istered swabs and the Nugent scoring method in early pregnancy,
at 32 weeks’ gestation and three months postpartum.
Neonatal outcomes
Four follow-up studies of four included trials reported neonatal
outcomes.
Dijkhuizen 2001 assessed neonatal outcomes in a trial de-
scribed previously, Dijkhuizen 2004. Outcomes described in-
cluded preterm delivery, stillbirth, neonatal mortality and low
birthweight.
Edmond 2012 conducted a follow-up study of the trial in Ghana
(Kirkwood 2010) and assessed the effects of vitamin A supplemen-
tation on neonatal mortality (< one month) expressed per 1000
live births amongst other neonatal outcomes.
Christian 2013 conducted a follow-up study of the West 2011
trial to assess the effects of maternal weekly vitamin A and beta-
carotene supplementation on birthweight, and length of gestation,
including preterm birth.
Prawirohartono 2013 is a follow-up study of the Hakimi 1999
trial. Out of 2173 supplement pregnant women, 1956 neonates
were assessed to determine whether vitamin A and/or zinc supple-
ment given during pregnancy improved birthweight or neonatal
morbidity. Neonatal morbidity included neonatal clinical infec-
tion by using measurements of fever, hypothermia, diarrhoea, and
vomiting in neonates up to 20 days of life.
Excluded studies
For detailed characteristics of the excluded trials, seeCharacteristics
of excluded studies.
Of the 15 excluded studies, we excluded two because they used
lycopene as the intervention (Banerjee 2009; Sharma 2003). Ly-
copene lacks beta ion ring (that is present in the beta-carotene),
so lycopene cannot form vitamin A and its biological effects are
due to mechanisms other than forming vitamin A. One study
was excluded as the intervention was unfortified soybean oil and
did not include vitamin A or any of its derivatives (Alam 2010).
We excluded three studies because they were not randomised tri-
als (Chawla 1995; Howells 1986; Laitinen 2009). We excluded
four studies because both arms of the trial contained the same
product and so lacked any comparison (Christian 2003; Haskell
2005; Lietz 2001; Roberfroid 2010). We excluded three studies
because the intervention only started after delivery (Darboe 2007;
Humphrey 2006; Roy 1997). We excluded one study because the
only outcome was HIV transmission and although secondary out-
comes are relevant to this review, no data are available (Chikobvu
2001).We excluded one study because participants were not preg-
nant women (Van Vliet 2001).
Risk of bias in included studies
See Figure 1 and Figure 2.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Three of the included studies did not report adequate meth-
ods for either random sequence generation or allocation con-
cealment (Green 1931; Sun 2010; Suprapto 2002) Six of the
included studies were not clear regarding both the allocation
concealment and the random sequence generation (Ajans 1965;
Coutsoudis 1999; Cox 2005; Muslimatun 2001; Radhika 2003;
Tanumihardjo 2002). Three studies were not clear simply with
regards to the random sequence generation, but did report ad-
equate allocation concealment (Dijkhuizen 2004; Fawzi 1998;
Suharno 1993).The remaining seven trials reported adequate al-
location concealment and generation (Hakimi 1999; Kirkwood
2010; Kumwenda 2002; Semba 2001; van den Broek 2006; West
1999; West 2011).
Blinding
Only two studies reported no blinding of participants and person-
nel and were unclear regarding the blinding of the outcome (Ajans
1965; Green 1931).
Eleven studies described blinding of participants and personnel,
but blinding for outcome assessment was unclear (Coutsoudis
1999; Cox 2005; Kirkwood 2010; Kumwenda 2002;Muslimatun
2001;Radhika 2003; Semba2001; Suharno 1993; Suprapto 2002;
Tanumihardjo 2002; West 1999).
One study Sun 2010 was not clear regarding the blinding of the
outcome only but did report adequate blinding of participants and
personnel.
The remaining five studies reported adequate double blinding
and outcome assessment (Dijkhuizen 2004; Fawzi 1998; Hakimi
1999; van den Broek 2006; West 2011).
Incomplete outcome data
Three studies were high risk of attrition bias (Hakimi 1999;
Muslimatun 2001; Semba 2001), with the remaining 16 included
trials adequately addressed the issue of incomplete outcome data
andwere low risk. the authors of the Kirkwood 2010 trial provided
supplementary data to confirm that although 43% of women mi-
grated out of the trial area and 1% withdrew consent, the loss
to follow-up for pregnancy-related mortality was calculated to be
8%.
Selective reporting
The protocols of the other included studies were not generally
available and accordingly we cannot comment on selective report-
ing bias except for West 2011 which was free from any selective
reporting bias.
Other potential sources of bias
Three studies were unclear regarding potential sources of bias
(Cox 2005; Sun 2010; Tanumihardjo 2002), either because, pres-
ence of differences in educational level and gestational age at en-
rolment (Cox 2005) or the study report is not detailed enough
(Tanumihardjo 2002). Three trials had a potential source of bias
which were reported (Ajans 1965; Hakimi 1999; Suprapto 2002)
The rest of the included trials were free from any potential source
of bias.
Effects of interventions
See: Summary of findings for the main comparison Vitamin
A alone versus placebo or no treatment; Summary of findings
2 Combination vitamin A and micronutrients for maternal and
newborn mortality and morbidity
1. Vitamin A alone versus placebo or no treatment
Primary outcomes
Vitamin A supplementation does not significantly affect the risk of
maternal mortality (risk ratio (RR) 0.88, 95% confidence interval
(CI) 0.65 to 1.20, four studies; Tau² = 0.04, I² = 50%, 101,574
women; Analysis 1.1) or perinatal mortality (RR 1.01, 95% CI
0.95 to 1.07; one study, 76,176 women; Analysis 1.2).
Secondary outcomes
Vitamin A supplementation does not significantly affect the risk of
neonatal mortality (RR 0.97, 95% CI 0.90 to 1.05; three studies
, I² = 23%, 89,556 women; Analysis 1.3), or stillbirth (RR 1.04,
95% CI 0.98 to 1.10, two studies,122,850 women; Analysis 1.4).
Vitamin A supplementation reduces the risk of maternal anaemia
(RR 0.64, 95% CI 0.43 to 0.94; three studies, Tau² = 0.08, I² =
68%, 3,818 women; Analysis 1.5), maternal clinical infection (RR
0.45, 95% CI 0.20 to 0.99; five studies, Tau² = 0.59, I² = 88%,
1,918 women; Analysis 1.6 ), and maternal night blindness (RR
0.79, 95% CI 0.64 to 0.98; two studies, 10,608 women; Analysis
1.7).
Vitamin A supplementation does not significantly affect the risk of
neonatal anaemia (RR 0.99, 95% CI 0.92 to 1.08, one study, 409
women; Analysis 1.9), preterm birth (RR 0.98, 95% CI 0.94 to
1.01, five studies, I² = 29%, 40,137 women; Analysis 1.8), or the
risk of having a low birthweight baby (RR 1.02, 95% CI 0.89 to
1.16, four studies, Tau² = 0.00, I² = 10%, 14,599 women; Analysis
1.12).
Neonatal clinical infection or congential malformations were not
reported in the studies.
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2. Vitamin A alone versus micronutrient supplements
without vitamin A
Primary outcomes
No trial investigated maternal or perinatal mortality as primary
outcomes for vitamin A alone versus micronutrient supplements
without vitamin A.
Secondary outcomes
Vitamin A alone compared tomicronutrient supplements without
vitamin A does not decrease maternal clinical infection (RR 0.99,
95% CI 0.83 to 1.18, two studies, I² = 0%, 591 women) Analysis
2.6. No other secondary outcomes were reported.
3. Vitamin A with other micronutrients versus
micronutrient supplements without vitamin A
Primary outcomes
Vitamin A supplementation (with other micronutrients) does not
decrease perinatal mortality (RR 0.51, 95% CI 0.10 to 2.69; one
study, 179 women) Analysis 3.2. Maternal mortality was not re-
ported.
Secondary outcomes
Vitamin A supplementation (with other micronutrients) does not
decrease maternal anaemia (RR 0.86, 95% CI 0.68 to 1.09; three
studies, 706 women) Analysis 3.5, or maternal clinical infection
(RR 0.95, 95% CI 0.80 to 1.13; I² = 45%, two studies, 597
women) Analysis 3.6.
Vitamin A supplementation (with other micronutrients) does not
decrease neonatal mortality (RR 0.65, 95% CI 0.32 to 1.31; one
study, 594 women) Analysis 3.3, stillbirth (RR 1.41, 95% CI 0.57
to 3.47; two studies, 866 women) Analysis 3.4, preterm birth (RR
0.39, 95% CI 0.08 to 1.93; one study, 136 women) Analysis 3.8,
neonatal anaemia (RR 0.75, 95% CI 0.38 to 1.51; Tau² = 0.24,
I² = 97%; two studies, 1052 women) Analysis 3.9, congential
malformations (RR 0.34, 95% CI 0.04 to 3.18; one study, 179
women) Analysis 3.11, or low birthweight (RR 0.67, 95%CI 0.47
to 0.96; one study, 594 women) Analysis 3.12.
Subgroup analysis
Only the specified primary outcomes maternal and perinatal mor-
tality were included in the subgroup analysis. Subgroup analysis
was by country statistics for vitamin A deficiency (high or low),
maternal mortality (high or low), infant morality (high or low),
and HIV status (high or low).
All trials investigating the effects on maternal and perinatal mor-
tality were cluster-randomised trials.
Subgroup analysis for vitamin A alone versus placebo
or no treatment
Countries with high versus low infant mortality rates (high
infant mortality rate greater than or equal to 30/1000 live
births (IMCI- TAG 2008)).
Perinatal mortality in countries with high infant mortality rates
remained unchanged (RR 1.01, 95% CI 0.95 to 1.07, one study,
76,176 women) Analysis 4.1. Perinatal mortality was not assessed
in countries with low infant mortality rates.
Perinatal mortality in countries with high maternal mortality rates
or high prevalence of vitamin A deficiency remained unchanged
(RR 0.95, 95% CI 0.87 to 1.03, one study, 73,743 women)
Analysis 4.4. No trials reported on perinatal mortality from coun-
tries with lowmaternal mortality rates or countries with low preva-
lence of vitamin A deficiency.
Countries with high versus low maternal mortality rates
(high maternal mortality rate greater than 100 per 100,000
live births (WHR 2005)).
In countries with high maternal mortality, the RR for maternal
mortality was 0.91, (95% CI 0.76 to 1.08, four studies, I²=55%,
161,240 women) Analysis 4.3 in the overall analysis. There was
no interaction between countries with lowmaternal mortality and
countries with high maternal mortality (Test for subgroup differ-
ences P = 0.54, I² = 0%). Maternal mortality rate did not change
in countries with low infant mortality (RR 0.33, 95% CI 0.01 to
9.44, one study, 550 women) Analysis 4.2.
High versus low prevalence of vitamin A deficiency (as
defined by WHO for the country or by the investigator).
Maternal mortality demonstrated no changes in countries with
low (RR 0.33, 95% CI 0.01 to 8.15; one study, 550 women),
or high (RR 0.88, 95% CI 0.63 to 1.23; three studies, 160,690
women; I² = 68%) prevalence of vitamin A deficiency Analysis
4.5.
Perinatal mortality showed no changes in countries with high
prevalence of vitamin A deficiency (RR 1.01, 95% CI 0.95 to
1.07; one study, 76,176 women) Analysis 4.6 .
Countries with a low versus high prevalence of HIV in the
general population (high-prevalence countries defined as
countries with national prevalence that exceeded 3% of the
general population.
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In countries with low HIV prevalence the RR for maternal mor-
tality was (RR 0.87, 95% CI 0.64 to 1.20, four studies, I² = 55%,
161,240 women) Analysis 4.7. The trials in countries with high
HIV prevalence did not set out to assess the effect of vitamin A
on maternal mortality.
In countries with low HIV prevalence, RR for perinatal mortal-
ity was 1.01 (95% CI 0.95 to 1.07, one study, 76,176 women)
Analysis 4.8. For countries with high HIV prevalence, no trials in-
vestigated the effect of vitamin A supplementation to the mother
on perinatal mortality.
Dose and regimen of vitamin A
In relation to the dose, no trials investigated the effect of daily
10,000 IU vitamin A supplementation on maternal mortality, but
for other doses the RR for vitaminA supplementation formaternal
mortality was (RR 0.88, 95% CI 0.63 to 1.23, three studies, I2 =
68%, 160,690 women), and for perinatal mortality 1.01 (95% CI
0.95 to 1.07, one study, 76,176 women), Analysis 4.9; Analysis
4.10.
For daily vitamin A supplementation, the RR for maternal mortal-
ity was 0.33 (95% CI 0.01 to 8.15) and weekly supplementation
was 0.88 (95% CI 0.63 to 1.23, four studies, I² = 55%, 161,240
women), Analysis 4.11. For weekly vitamin A supplement, the RR
for perinatal mortality was 1.01 (95% CI 0.95 to 1.07, one study,
76,176 women), Analysis 4.12.
Duration of intervention
There was no difference in the duration of the intervention of
vitamin A supplementation on maternal mortality; for one month
or less, the RR was 0.33, 95% CI 0.01 to 8.15, one study, 550
women) and more than one month RR was (RR 1.18, 95% CI
0.83 to 1.68, one study, 59,666 women), Analysis 4.13. No trial
assessed the effect of the duration of intervention with vitamin A
supplementation on perinatal mortality.
Trimester of pregnancy
There was no trial to assess vitamin A supplementation started in
the second trimester on the maternal mortality. However, the RR
of vitamin A on maternal mortality started in pre-pregnancy was
RR 0.77, (95% CI 0.50 to 1.17, two studies, I2 = 71%, 101,024
women), first trimester was RR 1.18, (95% CI 0.83 to 1.68, one
study, I² = 0%, 59,666 women), and third trimester was RR 0.33,
(95% CI 0.01 to 8.15, one study, 550 women), Analysis 4.15.
Although, there was no subgroup interaction in Analysis 4.15 (P=
0.25, I²=28.3%).
One trial assessed the vitamin A supplementation started in pre-
pregnancy on perinatal mortality (RR 1.01, 95% CI 0.95 to 1.07,
one study, 76,176 women), Analysis 4.16.
Sensitivity analysis
Randomisation
No individual-randomised trial assessed the effect of vitamin A
supplementation on maternal and perinatal mortality. For cluster-
randomisation trials the RR of vitamin A on was 0.88, (95% CI
0.63 to 1.23, three studies, I² = 68%, 160,690 women) and 1.01,
(95% CI 0.95 to 1.07, one study, 76,176 women) respectively,
Analysis 4.17; Analysis 4.18.
Subgroup analysis for vitamin A (with other
micronutrients) versus micronutrient supplements
without vitamin A
For all subgroup analysis, the RR of vitamin A supplementation
(with othermicronutrients) on perinatal mortality was 0.51, (95%
CI 0.10 to 2.69, one study, 179 women) Analysis 6.2. There were
no data on maternal mortality for these subgroups.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Combination vitamin A and micronutrients for maternal and newborn mortality and morbidity
Patient or population: Pregnant women
Settings: Areas with endemic vitamin A deficiency (inadequate intake)/areas with adequate intake as defined by the WHO global database on vitamin A deficiency
Intervention: Combination vitamin A and micronutrients
Comparison: Other micronutrients
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with micronutrient
supplements without vi-
tamin A
Risk with vitamin A with
other micronutrients
Maternal mortality Study population not estimable (0 studies) See comment No study reported results
for this outcome.
not pooled not pooled
Perinatal mortality Study population RR 0.51
(0.10 to 2.69)
179
(1 RCT)
⊕⊕©©
LOW 1
44 per 1000 23 per 1000
(4 to 120)
Moderate
44 per 1000 23 per 1000
(4 to 119)
Maternal anaemia Study population RR 0.86
(0.68 to 1.09)
706
(3 RCTs)
⊕⊕©©
LOW 2
269 per 1000 231 per 1000
(183 to 293)
Moderate
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346 per 1000 298 per 1000
(235 to 377)
Maternal clinical infection Study population RR 0.95
(0.80 to 1.13)
597
(2 RCTs)
⊕⊕©©
LOW 2
382 per 1000 363 per 1000
(306 to 432)
Moderate
339 per 1000 322 per 1000
(271 to 383)
Preterm birth Study population RR 0.39
(0.08 to 1.93)
136
(1 RCT)
⊕⊕©©
LOW 2
75 per 1000 29 per 1000
(6 to 144)
Moderate
75 per 1000 29 per 1000
(6 to 144)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Wide confidence interval crossing the line of no effect, few events & small sample size.
2 Wide confidence interval crossing the line of no effect & small sample size.
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D I S C U S S I O N
Summary of main results
This review investigates the effectiveness of vitamin A supplemen-
tation during pregnancy, alone or in combination with other mi-
cronutrients, on maternal and newborn clinical outcomes.
Nineteen trials are included in this review out of a total of 35 trials.
In countries where night blindness is reported, maternal night
blindness is significantly improved with vitamin A supplementa-
tion.
Overall, the analysis shows that there is no evidence that vitamin
A supplementation to women of reproductive age or during preg-
nancy decreases maternal mortality. The three largest studies from
Nepal, Ghana and Bangladesh specifically assessed the effect on
maternal mortality with over 153,500 women included. Vitamin
A deficiency is considered to be endemic inNepal and night blind-
ness is commonly reported. The main trial from Nepal by West
1999 reported a substantial reduction in pregnancy-related mor-
tality (including injuries) with most of the mortality contributing
to the difference between supplementation and placebo groups oc-
curring in death from injury, chronic illness and uncertain cause of
death, which was difficult to explain. Two subsequent large stud-
ies, both conducted in countries with moderate vitamin A defi-
ciency (Ghana and Bangladesh), did not show an effect of vitamin
A supplementation on maternal mortality.
In vitamin A deficient populations and HIV-positive women, vi-
tamin A supplementation reduces maternal anaemia and there is
evidence that vitamin A supplements alone may reduce maternal
clinical infection.
Several trials specifically assessed the effect of vitamin A supple-
mentation during the antenatal period on maternal anaemia. Vi-
tamin A was given together with other micronutrients, principally
iron and folic acid. The Malawi study reported no effect of vita-
min A in addition to iron supplementation on haemoglobin (Hb)
levels. Assessment of vitamin A status revealed the women were
generally vitamin A replete. The other three studies were from
countries where vitamin A deficiency is considered to be endemic
(Indonesia and Nepal), and from Tanzania, where the population
studied were all HIV-positive women. For the three studies in-
cluded in the meta-analysis, for a total of almost 2500 pregnant
women, maternal anaemia (Hb < 11.0g/dL) was found to be re-
duced.
Five studies measured maternal infection after supplementation
with vitamin A in just under 1800 women. It was noted that the
criteria for the outcome ’infection’ varied between the studies. We
note that one study included in the analysis is from a draft of a
publication which was not published in any peer review journal.
In one trial, the proxy measurements of interleukin 2 (IL-2) level
and lymphocyte proliferation were used to as an indirect measure
of the maternal ability to combat infection. The most significant
study included in the meta-analysis was conducted in the 1930s
(Green 1931) and there are questions related to the accuracy of
the design of this study. Also, it has not been possible to calculate
the exact dosage of vitamin A given (in the form of radiostoleum).
In addition, it must be noted that one of the three studies was
in HIV-positive women, who may have a different overall risk of
infection compared to non-HIV-positive women.
Of the included trials, 15 were designed to measure the effect of
vitamin A supplementation during pregnancy on maternal mor-
tality or maternal anaemia or maternal infection. Other maternal
and neonatal clinical outcomes were also determined in the stud-
ies but not as primary outcomes. Three trials were designed to
assess the effect of vitamin A on mother to child transmission of
HIV. We have included these because the secondary outcomes are
relevant to this review.
No studies of supplementation in the antenatal period were specif-
ically designed to assess neonatal outcomes, but where these were
reported we have included them in the analyses. For studies re-
porting these outcomes, vitamin A supplementation alone does
not affect the risk of perinatal mortality or stillbirth or neonatal
mortality separately. Similarly, analysis of available data shows no
effect on pretermbirth or low birthweight. There were no reported
side effects or adverse events in any of the trials. One study did
report on congential abnormalities but the effect was not signifi-
cant. For one study supplementing vitamin A together with other
micronutrients (versus other micronutrients in control group) in
HIV-positive women, the risk of low birthweight was found to
reduced.
The trials are from a variety of countries, including high-, mid-
dle- and low-income countries, with large differences between the
countries with regard to baseline maternal and perinatal mortal-
ity as well as baseline vitamin A status and prevalence of anaemia
of the populations studied. In some studies vitamin A status of
the trial population was assessed specifically at baseline (by serum
retinol levels or using the more accurate modified relative dose
response test), whereas in other studies this was not done.
It was difficult to compare the results of supplementation with
vitamin A (or derivatives) on maternal and newborn health out-
comes, especially where these outcomes were differently defined in
the different studies. For example, maternal clinical infection was
variously defined as temperature above 37 or 38 degrees Celsius at
different times during pregnancy and the postnatal period (e.g. 12
weeks antenatal or one week or three months postnatal); or infec-
tious morbidity was defined by recorded diagnosis (gastroenteritis,
sepsis, respiratory infection, etc). In one trial, the proxy measure-
ments of interleukin 2 (IL-2) level and lymphocyte proliferation
were used as an indirect measure of the maternal ability to combat
infection. The data from this trial were continuous, and could not
be combined with other studies with dichotomous outcome data
and hence this study did not contribute any data to the review
results.
Maternal anaemia was more consistently defined (Hb < 11.0 g/dL,
Hb < 10.0 g/dL). However, one study fromMalawi and one from
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China reported change in Hb rather than percentage of women
not anaemic and thus we have not included it in themeta-analysis.
The dose of vitamin A given, in combination with additional
micronutrients and the duration of supplementation differed in
the trials and varied between 5000 IU and 10,000 IU for daily
doses, around 200,000 IU vitamin A for weekly supplementation
and 200,000 IU vitamin A at time of delivery.
There were no differences in outcomes for any of the subgroup
analyses performed.
Overall completeness and applicability of
evidence
The three cluster-randomised trials with a large number of partic-
ipants were included in the meta-analysis and increased the accu-
racy and reliability of the evidence produced. Added to that, the
different populations studied by different included randomised
clinical trials amplified the applicability of the evidence produced.
Most of the specified outcomes were reported by some of the in-
cluded trials but the different trials were not designed to measure
the same primary outcomes and many of the specified secondary
outcomes were either not reported and/or defined differently in
the different country settings. The underlying baseline statistics
for maternal mortality, perinatal mortality and vitamin A status
of pregnant women were not available for the specific population
studies, and country estimates were therefore used in most cases.
Quality of the evidence
In the majority of studies, adequate methods of allocation con-
cealment were described; only three trials described inadequate
methods (Green 1931; Sun 2010; Suprapto 2002). Green 1931
and Suprapto 2002 used an alternation method for the alloca-
tion generation and concealment; marking each first woman as
a participant and the next woman due to deliver as the control.
Suharno 1993 did not report how the allocation was generated
or concealed. In Sun 2010 women were randomised in order of
enrolment. In the case of blinding, all trials included were dou-
ble blinded except Ajans 1965 and Green 1931, both of which
did not use any intervention in the control group. Three clinical
trials included lost more than 20% of the participants (Hakimi
1999; Muslimatun 2001; Semba 2001); these clinical trials were
conducted in rural areas with participants moving in and out of
the study area. None of the included trials were stopped early.
Accordingly, none of the included trials suffered any limitation at
the design or implementation level. Furthermore, all the included
trials directly compared the effects of vitamin A supplementation
on the mother and baby.
Heterogenity between trials in themeta-analysis was minimal (0%
to 40%). Added to that, the precision of the results can be consid-
ered good, with narrow confidence intervals in most cases except
for the subgroup analyses.
The overall risk of bias is low to unclear for most of the studies.
For comparison vitamin A alone versus placebo or no treatment,
the quality of the evidence as assessed using GRADE was high for
maternal mortality, perinatal mortality, and preterm birth, mod-
erate for maternal anaemia and low for maternal clinical infec-
tion (Summary of findings for the main comparison). Reasons for
downgrading the evidence include statistical heterogeneity and de-
sign limitations. For combination vitamin A and micronutrients,
due to wide confidence interval crossing the line of no effect, few
events and small sample size, all the outcomes were rated as low
quality of the evidence (Summary of findings 2).
Potential biases in the review process
We acknowledge that there was the potential for bias at all stages in
the reviewing process.We attempted tominimise bias in a number
ofways; for example, two review authors independently carried out
data extraction and assessed risk of bias. However, we acknowledge
that such assessments involve subjective judgments, and another
review team may not have agreed with all of our decisions.
Agreements and disagreements with other
studies or reviews
The trials included in this review were carefully planned and exe-
cuted.
The absence of an effect on stillbirth rate, neonatal mortality,
or perinatal mortality accords with the findings of the two large
cluster trials (Cox 2005; Kirkwood 2010).
It has been suggested that vitamin A supplementation, especially
in the postpartum period, will reduce the incidence of sepsis. In
the trials reviewed, maternal clinical infection was assessed in a
number of ways and there is evidence to suggest that vitamin A
could have a significant effect on maternal infection.
Maternal anaemia evidence is of high quality with data to support
that supplementation with vitamin A reduces anaemia in vitamin
A deficient and HIV-positive women.
There are no reports of side effects or adverse events in the trials
published so far.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Overall, the findings of this review do not currently support a
role for antenatal vitamin A supplementation to reduce maternal
or perinatal mortality. There is, however, evidence that antenatal
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vitamin A supplementation (in addition to iron and folic acid)
reduces maternal anaemia in populations that are vitamin A defi-
cient, and in HIV-positive pregnant women. Although the avail-
able evidence suggests a reduction in maternal infection when vi-
tamin A is given antenatally or around the time of delivery, the
data are not of a high quality and further evidence is needed to
explore the effect of antenatal vitamin A supplementation on ma-
ternal infection in the antenatal and postnatal periods. The effect
of vitamin A is likely to depend on whether the population who
receive supplements are vitamin A deficient or not.
Implications for research
Results of 19 trials to assess effect of vitamin A supplementation
during pregnancy are presented in this review. The three main
outcomes examined are maternal mortality, maternal anaemia and
maternal infection.
It must be said that for any of these individual outcomes there
were between two and four trials that could be included in a meta-
analysis and even within this group of trials there was significant
difference in population with regard to vitamin A status, baseline
anaemia and infection prevalence and maternal mortality ratio.
It seems unlikely that vitamin A supplementation per se con-
tributes directly to reducing maternal mortality. The evidence that
thismight be possible originally came from the trial inNepal where
vitaminA deficiency is commonbut reduction in deaths was not in
the category of direct maternal deaths. In Ghana and Bangladesh
this is less likely as women are moderately vitamin A deficient
and supplementation did not reduce mortality. In the study from
Ghana there was a substantial number of women lost to follow-
up. In all three trials, (Ghana and Nepal and Bangladesh) results
are in the same direction (a reduction in maternal mortality). The
trials from Ghana and Bangladesh showed non-significant results.
In Ghana, 43% of womenmigrated outside the study area and 1%
withdrew consent. These women contributed to the final analysis
either by completing a pregnancy before they migrated or con-
tributed data to the analysis of all-cause female mortality by con-
tributing person time to the denominator of this analysis. Loss to
follow-up for pregnancy-related mortality was subsequently calcu-
lated to be 8% (supplementary information provided by authors).
For Nepal, the reduction in deaths is difficult to explain with bio-
logical plausibility, but it was a significant reduction. The baseline
vitamin A status in each of these trials was not assessed. Vitamin A
deficiency in Nepal is considered to be severe, whereas for Ghana
and Bangladesh this is considered to be moderate. For populations
with no or less deficiency in vitamin A, supplementation is likely
to be less effective.
It would seem that if any new trials are designed, it will be crucially
important to assess baseline vitamin A status as well as accurate
cause of maternal (and neonatal) death and to ensure follow-up
of women is possible. In resource-poor settings where maternal
mortality is highest and research most needed, this will also be
most difficult to ensure.
Further high-quality evidence on whether vitamin A can reduce
infection including maternal sepsis is needed.
To improve haemoglobin (Hb), vitamin A supplementation in
addition to iron and folic acid is beneficial in women who are
vitamin A deficient or HIV-positive. The optimal dose of vitamin
A, length of supplementation and themaximum expected increase
in Hb have not been established. Also effect change will depend
on baseline degree of anaemia and vitamin A deficiency, and this
requires further study.
Itwas noted that there are differences between the trialswith regard
to the dose of vitamin A given, the combination with additional
micronutrients and the duration of supplementation. In addition,
baseline assessments of vitamin A status are often not available
even outside the study population, methods of assessment vary
and comparisons are therefore very difficult to make. For future
studies it is recommended that these are designed to take account
of these limitations. It would also be helpful if neonatal outcomes
are measured according to international criteria so that studies can
be compared.
A C K N OW L E D G E M E N T S
Lisa Hurt, on behalf of the ObaapaVitA trial team, for providing
additional data about the Kirkwood 2010 trial.
We thank ErikaOta for her help with the 2015 update. ErikaOta’s
workwas financially supported by theUNDP/UNFPA/UNICEF/
WHO/World Bank Special Programme of Research, Develop-
ment and ResearchTraining inHuman Reproduction (HRP), De-
partment of Reproductive Health and Research (RHR), World
Health Organization. The named authors alone are responsible
for the views expressed in this publication.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Preg-
nancy and Childbirth. The views and opinions expressed therein
are those of the authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, NHS or the Department
of Health.
25Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Ajans 1965 {published data only}
Ajans ZA, Sarrif A, Husbands M. Influence of vitamin A
on human colostrum and early milk. American Journal of
Clinical Nutrition 1965;17:139–42.
Coutsoudis 1999 {published data only}
Coutsoudis A, Moodley D, Pillay K, Harrigan R, Stone C,
Moodley J, et al. Effects of vitamin A supplementation
on viral load in HIV-1 infected pregnant women. Journal
of Acquired Immune Deficiency Syndromes and Human
Retrovirology 1997;15(1):86–7.
∗ Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia
HM. Randomized trial testing the effect of vitamin A
supplementation on pregnancy outcomes and early mother-
to-child HIV-1 transmission in Durban, South Africa.
AIDS 1999;13(12):1517–24.
Filteau SM, Rollins NC, Coutsoudis A, Sullivan KR,
Willumsen JF, Tomkins AM. The effect of antenatal vitamin
A and beta-carotene supplementation on gut integrity of
infants of HIV-infected South African women. Journal
of Pediatric Gastroenterology and Nutrition 2001;32(4):
464–70.
Kennedy CM, Coutsoudis A, Kuhn L, Pillay K, Mburu A,
Stein Z, et al. Randomized controlled trial assessing the
effect of vitamin A supplementation on maternal morbidity
during pregnancy and postpartum among HIV-infected
women. Journal of Acquired Immune Deficiency Syndromes
2000;24(1):37–44.
Kennedy-Oji C, Coutsoudis A, Kuhn L, Pillay K, Mburu A,
Stein Z, et al. Effects of vitamin A supplementation during
pregnancy and early lactation on body weight of South
African HIV-infected women. Journal of Health, Population
& Nutrition 2001;19(3):167–76.
Kuhn L, Coutsoudis A, Trabattoni D, Archary D, Rossi T,
Segat L, et al. Synergy between mannose-binding lectin
gene polymorphisms and supplementation with vitamin A
influences susceptibility to HIV infection in infants born
to HIV-positive mothers. American Journal of Clinical
Nutrition 2006;84(3):610–5.
Cox 2005 {published data only}
Cox SE, Arthur P, Kirkwood BR, Yeboah-Antwi K, Riley
EM. Vitamin A supplementation increases ratios of
proinflammatory to anti-inflammatory cytokine responses
in pregnancy and lactation. Clinical & Experimental
Immunology 2006;144(3):392–400.
∗ Cox SE, Staalsoe T, Arthur P, Bulmer JN, Tagbor H, Hviid
L, et al. Maternal vitamin A supplementation and immunity
to malaria in pregnancy in Ghanaian primigravids. Tropical
Medicine & International Health 2005;10(12):1286–97.
Dijkhuizen 2004 {published data only}
Dijkhuizen MA. Vitamin A, Iron and Zinc Deficiency
in Indonesia. Micronutrient Interactions and Effects of
Supplementation [thesis]. Wageningen University, 2001.
∗ Dijkhuizen MA, Wieringa FT, West CE, Muhilal.
Zinc plus beta-carotene supplementation of pregnant
women is superior to beta-carotene supplementation
alone in improving vitamin A status in both mothers and
infants. American Journal of Clinical Nutrition 2004;80(5):
1299–307.
Wieringa FT, Dijkhuizen MA, Muhilal, Van der Meer JW.
Maternal micronutrient supplementation with zinc and
beta-carotene affects morbidity and immune function of
infants during the first 6 months of life. European Journal of
Clinical Nutrition 2010;64(10):1072–9.
Fawzi 1998 {published data only}
Arsenault JE, Aboud S, Manji KP, Fawzi WW, Villamor
E. Vitamin supplementation increases risk of subclinical
mastitis in HIV-infected women. Journal of Nutrition 2010;
140(10):1788–92.
Baylin A, Villamor E, Rifai N, Msamanga G, Fawzi
WW. Effect of vitamin supplementation to HIV-infected
pregnant women on the micronutrient status of their
infants. European Journal of Clinical Nutrition 2005;59(8):
960–8.
Fawzi W, Msamanga G, Antelman G, Xu C, Hertzmark
E, Spiegelman D, et al. Effect of prenatal vitamin
supplementation on lower-genital levels of HIV type 1 and
interleukin type 1 beta at 36 weeks of gestation. Clinical
Infectious Diseases 2004;38(5):716–22.
Fawzi WW, Msamanga G, Hunter D, Urassa E, Renjifo
B, Mwakagile D, et al. Randomized trial of vitamin
supplements in relation to vertical transmission of HIV-1 in
Tanzania. Journal of Acquired Immune Deficiency Syndromes
2000;23(3):246–54.
Fawzi WW, Msamanga GI, Hunter D, Renjifo B, Antelman
G, Bang H, et al. Randomized trial of vitamin supplements
in relation to transmission of HIV-1 through breastfeeding
and early child mortality. AIDS (London, England) 2002;16
(14):1935–44.
Fawzi WW, Msamanga GI, Kupka R, Spiegelman D,
Villamor E, Mugusi F, et al. Multivitamin supplementation
improves hematologic status in HIV-infected women and
their children in Tanzania. American Journal of Clinical
Nutrition 2007;85(5):1335–43.
Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ,
Hunter DJ. Rationale and design of the Tanzania Vitamin
and HIV Infection Trial. Controlled Clinical Trials 1999;20
(1):75–90.
∗ Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ,
McGrath N, Mwakagile D, et al. Randomised trial of
effects of vitamin supplements on pregnancy outcomes and
T cell counts in HIV-1-infected women in Tanzania. Lancet
1998;351(9114):1477–82.
Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga
S, Villamor E, et al. A randomized trial of multivitamin
supplements and HIV disease progression and mortality.
New England Journal of Medicine 2004;351(1):23–32.
Fawzi WW, Msamanga GI, Wei R, Spiegelman D,
Antelman G, Villamor E, et al. Effect of providing vitamin
26Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
supplements to human immunodeficiency virus-infected,
lactating mothers on the child’s morbidity and cd4+ cell
counts. Clinical Infectious Diseases 2003;36(8):1053–62.
Kawai K, Kupka R, Mugusi F, Aboud S, Okuma J, Villamor
E, et al. A randomized trial to determine the optimal dosage
of multivitamin supplements to reduce adverse pregnancy
outcomes among HIV-infected women in Tanzania.
American Journal of Clinical Nutrition 2010;91(2):391–7.
Kawai K, Msamanga G, Manji K, Villamor E, Bosch RJ,
Hertzmark E, et al. Sex differences in the effects of maternal
vitamin supplements on mortality and morbidity among
children born to HIV-infected women in Tanzania. British
Journal of Nutrition 2010;103(12):1784–91.
Kupka R, Msamanga GI, Spiegelman D, Morris S, Mugusi
F, Hunter DJ, et al. Selenium status is associated with
accelerated HIV disease progression among HIV-1-infected
pregnant women in Tanzania. Journal of Nutrition 2004;
134(10):2556–60.
McGrath N, Bellinger D, Robins J, Msamanga GI,
Tronick E, Fawzi WW. Effect of maternal multivitamin
supplementation on the mental and psychomotor
development of children who are born to HIV-1-infected
mothers in Tanzania. Pediatrics 2006;117(2):216–25.
Merchant AT, Msamanga G, Villamor E, Saathoff
E, O’Brien M, Hertzmark E, et al. Multivitamin
supplementation of HIV-positive women during pregnancy
reduces hypertension. Journal of Nutrition 2005;135(7):
1776–81.
Olofin IO, Spiegelman D, Aboud S, Duggan C, Danaei
G, Fawzi WW. Supplementation with multivitamins and
vitamin A and incidence of malaria among HIV-infected
Tanzanian women. Journal of Acquired Immune Deficiency
Syndromes 2014;67(Suppl 4):S173–8.
Smith Fawzi MC, Kaaya SF, Mbwambo J, Msamanga GI,
Antelman G, Wei R, et al. Multivitamin supplementation
in HIV-positive pregnant women: impact on depression
and quality of life in a resource-poor setting. HIV Medicine
2007;8(4):203–12.
Villamor E, Koulinska IN, Aboud S, Murrin C, Bosch
RJ, Manji KP, et al. Effect of vitamin supplements on
HIV shedding in breast milk. American Journal of Clinical
Nutrition 2010;92(4):881–6.
Villamor E, Msamanga G, Saathoff E, Fataki M, Manji
K, Fawzi WW. Effects of maternal vitamin supplements
on malaria in children born to HIV-infected women.
American Journal of Tropical Medicine and Hygiene 2007;76
(6):1066–71.
Villamor E, Msamanga G, Saathoff E, Manji K, Fawzi WW.
Effect of vitamin supplements on the incidence of malaria
among children born to HIV-infected Women. FASEB
Journal 2006;20(4 Pt 1):A125.
Villamor E, Saathoff E, Bosch RJ, Hertzmark E, Baylin A,
Manji K, et al. Vitamin supplementation of HIV-infected
women improves postnatal child growth. American Journal
of Clinical Nutrition 2005;81(4):880–8.
Villamor E, Saathoff E, Manji K, Msamanga G, Hunter
DJ, Fawzi WW. Vitamin supplements, socioeconomic
status, and morbidity events as predictors of wasting in
HIV-infected women from Tanzania. American Journal of
Clinical Nutrition 2005;82(4):857–65.
Webb AL, Aboud S, Furtado J, Murrin C, Campos H, Fawzi
WW, et al. Effect of vitamin supplementation on breast
milk concentrations of retinol, carotenoids and tocopherols
in HIV-infected Tanzanian women. European Journal of
Clinical Nutrition 2009;63(3):332–9.
Green 1931 {published data only}
Green HN, Pindar D, Davis G, Mellanby E. Diet as a
prophylactic agent against puerperal sepsis. British Medical
Journal 1931;2:595–8.
Hakimi 1999 {unpublished data only}
∗ Hakimi M, Dibley M. ZIBUVITA trial: impact of vitamin
A and zinc supplementation in pregnancy on maternal post
partum infections. Personal communication 1999.
Prawirohartono EP, Nystrom L, Ivarsson A, Stenlund
H, Lind T. The impact of prenatal vitamin A and zinc
supplementation on growth of children up to 2 years of age
in rural Java, Indonesia. Public Health Nutrition 2011;14
(12):2197–206.
Prawirohartono EP, Nystrom L, Nurdiati DS, Hakimi
M, Lind T. The impact of prenatal vitamin A and zinc
supplementation on birth size and neonatal survival - a
double-blind, randomized controlled trial in a rural area of
Indonesia. International Journal for Vitamin and Nutrition
Research 2013;83(1):14–25.
Kirkwood 2010 {published data only}
Costello A, Osrin D. Vitamin A supplementation and
maternal mortality. Lancet 2010;375:1675–7.
Edmond K, Hurt L, Fenty J, Amenga-Etego S, Zandoh
C, Hurt C, et al. Effect of vitamin A supplementation in
women of reproductive age on cause-specific early and late
infant mortality in rural Ghana: ObaapaVitA double-blind,
cluster-randomised, placebo-controlled trial. BMJ Open
2012;2(1):e000658.
Hurt L, Ten Asbroek A, Amenga-Etego S, Zandoh C, Danso
S, Edmond K, et al. Effect of vitamin A supplementation
on cause-specific mortality in women of reproductive age
in Ghana: a secondary analysis from the ObaapaVitA trial.
Bulletin of the World Health Organization 2013;91(1):
19–27.
Kirkwood B. Trial of the impact of vitamin A on maternal
mortality (ObaapaVitA). http://clinicaltrials.gov/ct2/show/
NCT00211341 (accessed August 2010).
Kirkwood B. “ObaapaVitA” Vitamin A Supplementation
and Maternal Mortality Trial: Randomized double-
blind placebo controlled trial to evaluate the impact
of vitamin A supplementation maternal mortality in
Ghana. http://www.lshtm.ac.uk/nphir/research/obaapavita/
Obaapa˙Trial˙Protocol.pdf (accessed August 2010).
Kirkwood BR, Hurt L, Amenga-Etego S, Tawiah C, Zandoh
C, Danso S, et al. Effect of vitamin A supplementation in
women of reproductive age on maternal survival in Ghana
(ObaapaVitA): a cluster-randomised, placebo-controlled
trial. Personal communication.
∗ Kirkwood BR, Hurt L, Amenga-Etego S, Tawiah
27Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C, Zandoh C, Danso S, et al. Effect of vitamin A
supplementation in women of reproductive age on maternal
survival in Ghana (obaapavita): a cluster-randomised,
placebo-controlled trial. Lancet 2010;375(9726):1640–9.
Kumwenda 2002 {published data only}
Kumwenda N, Miotti PG, Taha TE, Broadhead R, Biggar
RJ, Jackson JB, et al. Antenatal vitamin A supplementation
increases birth weight and decreases anemia among infants
born to human immunodeficiency virus-infected women in
Malawi. Clinical Infectious Diseases 2002;35(5):618–24.
Muslimatun 2001 {published data only}
∗ Muslimatun S, Schmidt MK, Schultink W, West CE,
Hautvast JGAJ, Gross R, et al. Weekly supplementation
with iron and vitamin A during pregnancy increases
hemoglobin concentration but decreases serum ferritin
concentration in Indonesian pregnant women. Journal of
Nutrition 2001;131(1):85–90.
Muslimatun S, Schmidt MK, West CE, Schultink W, Gross
R, Hautvast JG. Determinants of weight and length of
Indonesian neonates. European Journal of Clinical Nutrition
2002;56(10):947–51.
Muslimatun S, Schmidt MK, West CE, Schultink W,
Hautvast JG, Karyadi D. Weekly vitamin A and iron
supplementation during pregnancy increases vitamin
a concentration of breast milk but not iron status in
Indonesian lactating women. Journal of Nutrition 2001;131
(10):2664–9.
Schmidt MK, Muslimatun S, Schultink W, West CE,
Hautvast JG. Randomised double-blind trial of the effect of
vitamin A supplementation of Indonesian pregnant women
on morbidity and growth of their infants during the first
year of life. European Journal of Clinical Nutrition 2002;56
(4):338–46.
Schmidt MK, Muslimatun S, West CE, Schultink W,
Hautvast JG. Mental and psychomotor development in
Indonesian infants of mothers supplemented with vitamin
A in addition to iron during pregnancy. British Journal of
Nutrition 2004;91(2):279–85.
Schmidt MK, Muslimatun S, West CE, Schultink W,
Hautvast JG. Vitamin A and iron supplementation of
Indonesian pregnant women benefits vitamin a status
of their infants. British Journal of Nutrition 2001;86(5):
607–15.
Radhika 2003 {published data only}
Radhika MS, Bhaskaram P, Balakrishna N, Ramalakshmi
BA. Red palm oil supplementation: a feasible diet-based
approach to improve the vitamin A status of pregnant
women and their infants. Food & Nutrition Bulletin 2003;
24(2):208–17.
Semba 2001 {published data only}
∗ Semba RD, Kumwenda N, Taha TE, Mtimavalye L,
Broadhead R, Garrett E, et al. Impact of vitamin A
supplementation on anaemia and plasma erythropoietin
concentrations in pregnant women: a controlled clinical
trial. European Journal of Haematology 2001;66(6):389–95.
Semba RD, Kumwenda N, Taha TE, Mtimavalye L,
Broadhead R, Miotti PG, et al. Plasma and breast milk
vitamin A as indicators of vitamin A status in pregnant
women. International Journal for Vitamin and Nutrition
Research 2000;70(6):271–7.
Suharno 1993 {published data only}
Suharno D, West CE, Muhilal, Karyadi D, Hautvast JG.
Supplementation with vitamin A and iron for nutritional
anaemia in pregnant women in West Java, Indonesia. Lancet
1993;342(8883):1325–8.
Sun 2010 {published data only}
Sun YY, Ma AG, Yang F, Zhang FZ, Luo YB, Jiang DC,
et al. A combination of iron and retinol supplementation
benefits iron status, IL-2 level and lymphocyte proliferation
in anemic pregnant women. Asia Pacific Journal of Clinical
Nutrition 2010;19(4):513–9.
Suprapto 2002 {published data only}
Suprapto B, Widardo, Suhanantyo. Effect of low-dosage
vitamin A and riboflavin on iron-folate supplementation in
anaemic pregnant women. Asia Pacific Journal of Clinical
Nutrition 2002;11(4):263–7.
Tanumihardjo 2002 {published data only}
Tanumihardjo SA. Vitamin A and iron status are improved
by vitamin A and iron supplementation in pregnant
Indonesian women. Journal of Nutrition 2002;132:
1909–12.
van den Broek 2006 {published data only}
van den Broek NR. Double-blind randomised trial of
antenatal vitamin A supplementation in pregnant anaemic
women in rural Malawi. Personal communication 1999.
∗ van den Broek NR, White SA, Flowers C, Cook JD,
Letsky EA, Tanumihardjo SA, et al. Randomised trial of
vitamin A supplementation in pregnant women in rural
Malawi found to be anaemic on screening by HemoCue.
BJOG: an international journal of obstetrics and gynaecology
2006;113(5):569–76.
West 1999 {published data only}
Checkley W, West KP Jr, Wise RA, Baldwin MR, Wu L,
LeClerq SC, et al. Maternal vitamin A supplementation
and lung function in offspring. New England Journal of
Medicine 2010;362(19):1784–94.
Christian P, Khatry SK, Yamini S, Stallings R, LeClerq SC,
Shrestha SR, et al. Zinc supplementation might potentiate
the effect of vitamin A in restoring night vision in pregnant
Nepalese women. American Journal of Clinical Nutrition
2001;73(6):1045–51.
Christian P, West KP Jr, Katz J, Kimbrough-Pradhan E,
LeClerq SC, Khatry SK, et al. Cigarette smoking during
pregnancy in rural Nepal. Risk factors and effects of beta-
carotene and vitamin A supplementation. European Journal
of Clinical Nutrition 2004;58(2):204–11.
Christian P, West KP Jr, Khatry SK, Katz J, LeClerq
S, Pradhan EK, et al. Vitamin A or beta-carotene
supplementation reduces but does not eliminate maternal
night blindness in Nepal. Journal of Nutrition 1998;128:
1458–63.
Christian P, West KP Jr, Khatry SK, Kimbrough-Pradhan E,
LeClerq SC, Katz J, et al. Night blindness during pregnancy
28Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and subsequent mortality among women in Nepal: effects
of vitamin A and beta-carotene supplementation. American
Journal of Epidemiology 2000;152:542–7.
Christian P, West KP Jr, Khatry SK, LeClerq SC,
Kimbrough-Pradhan E, Katz J, et al. Maternal night
blindness increases risk of mortality in the first 6 months of
life among infants in Nepal. Journal of Nutrition 2001;131
(5):1510–2.
Christian P, West KP, Khatry SK, Katz J, LeClerq SC,
Kimbrough-Pradhan E, et al. Vitamin a or beta-carotene
supplementation reduces symptoms of illness in pregnant
and lactating Nepali women. Journal of Nutrition 2000;
130:2675–82.
Congdon NG, Dreyfuss ML, Christian P, Navitsky RC,
Sanchez AM, Wu LS, et al. Responsiveness of dark-
adaptation threshold to vitamin A and beta-carotene
supplementation in pregnant and lactating women in Nepal.
American Journal of Clinical Nutrition 2000;72:1004–9.
Katz J, West KP Jr, Khatry SK, Christian P, LeClerq SC,
Pradhan EK, et al. Risk factors for early infant mortality
in Sarlahi district, Nepal. Bulletin of the World Health
Organization 2003;81(10):717–25.
Katz J, West KP Jr, Khatry SK, LeClerq SC, Christian P,
Pradhan EK, et al. Twinning rates and survival of twins in
rural Nepal. International Journal of Epidemiology 2001;30:
802–7.
Katz J, West KP Jr, Khatry SK, Pradhan EK, LeClerq SC,
Christian P, et al. Maternal low-dose vitamin A or B-
carotene supplementation has no effect on fetal loss and
early infant mortality: a randomized cluster trial in Nepal.
American Journal of Clinical Nutrition 2000;71:1570–6.
Olsen SF. Effect of vitamin a and beta carotene
supplementation on women’s health. BMJ 1999;318
(7183):551–2.
Palmer AC, Schulze KJ, West KP. Preconceptional through
post-partum vitamin A (VA) supplementation increases
natural antibody concentrations of offspring aged 9-13 years
in rural Nepal. FASEB Journal 2011;25:333.7.
Stewart CP, Christian P, Katz J, Schulze KJ, Wu LSF,
LeClerq SC, et al. Maternal supplementation with vitamin
A or B-carotene and cardiovascular risk factors among pre-
adolescent children in rural Nepal. Journal of Developmental
Origins of Health and Disease 2010;1(4):262–70.
Stewart CP, Christian P, Schulze KJ, Arguello M, Leclerq
SC, Khatry SK, et al. Low maternal vitamin B-12 status
is associated with offspring insulin resistance regardless of
antenatal micronutrient supplementation in rural Nepal.
Journal of Nutrition 2011;141(10):1912–7.
∗ West KP Jr, Katz J, Khatry SK, LeClerq SC, Pradhan EK,
Shrestha SR, et al. Double blind, cluster randomised trial of
low dose supplementation with vitamin A or beta carotene
on mortality related to pregnancy in Nepal: the nnips-2
study group. BMJ 1999;318(7183):570–5.
Yamini S,West KP Jr, Wu L, Dreyfuss ML, Yang DX, Khatry
SK. Circulating levels of retinol, tocopherol and carotenoid
in Nepali pregnant and postpartum women following
long-term beta-carotene and vitamin A supplementation.
European Journal of Clinical Nutrition 2001;55:252–9.
West 2011 {published data only}
Christian P, Klemm R, Shamim AA, Ali H, Rashid M,
Shaikh S, et al. Effects of vitamin A and beta-carotene
supplementation on birth size and length of gestation in
rural Bangladesh: a cluster-randomized trial. American
Journal of Clinical Nutrition 2013;97(1):188–94.
Christian P, Labrique AB, Ali H, Richman MJ, Wu
L, Rashid M, et al. Maternal vitamin A and beta-
carotene supplementation and risk of bacterial vaginosis: a
randomized controlled trial in rural Bangladesh. American
Journal of Clinical Nutrition 2011;94(6):1643–9.
Labrique AB, Christian P, Klemm RDW, Rashid M,
Shamim AA, Massie A, et al. A cluster-randomized,
placebo-controlled, maternal vitamin A or beta-carotene
supplementation trial in Bangladesh: design and methods.
Trials 2011;12:102.
Shaikh S, Schulze KJ, Ali H, Labrique AB, Shamim
AA, Rashid M, et al. Bioelectrical impedance among
rural Bangladeshi Women during pregnancy and in the
postpartum period. Journal of Health, Population &
Nutrition 2011;29(3):236–44.
∗ West KPJ, Christian P, Labrique AB, Rashid M, Shamim
AA, Klemm RD, et al. Effects of vitamin A or beta carotene
supplementation on pregnancy-related mortality and infant
mortality in rural Bangladesh: a cluster randomized trial.
JAMA 2011;305(19):1986–95.
References to studies excluded from this review
Alam 2010 {published data only}
Alam DS, van Raaij JM, Hautvast JG, Yunus M, Wahed
MA, Fuchs GJ. Effect of dietary fat supplementation during
late pregnancy and first six months of lactation on maternal
and infant vitamin A status in rural Bangladesh. Journal of
Health, Population & Nutrition 2010;28(4):333–42.
Banerjee 2009 {published data only}
Banerjee S, Jeyaseelan S, Guleria R. Trial of lycopene to
prevent pre-eclampsia in healthy primigravidas: results show
some adverse effects. Journal of Obstetrics and Gynaecology
Research 2009;35(3):477–82.
Chawla 1995 {published data only}
Chawla PK, Puri R. Impact of nutritional supplements on
hematological profile of pregnant women. Indian Pediatrics
1995;32:876–80.
Chikobvu 2001 {published data only}
Chikobvu P, Jouvert G, Schall R, Steinberg WJ, Viljoen
JI, Kotze M, et al. The effect of vitamin A on reducing
mother-to-child transmission of HIV in Bloemfontein. 21st
Conference on Priorities in Perinatal Care in South Africa;
2002 March 5-8; Eastern Cape, South Africa. 2002.
∗ Chikobvu P, van der Ryst E, Joubert G, Steinberg WJ,
Voljoen JI, Kriel J, et al. Preliminary results of a double
blind randomised controlled trial testing the effect of
vitamin A in mother to child transmission of HIV-1. 20th
Conference on Priorities in Perinatal Care in Southern
Africa; 2001 March 6-9; KwaZulu-Natal, South Africa.
2001.
29Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Christian 2003 {published data only}
Christian P, Darmstadt GL, Wu L, Khatry SK, LeClerq
SC, Katz J, et al. The effect of maternal micronutrient
supplementation on early neonatal morbidity in rural
Nepal: a randomised, controlled, community trial. Archives
of Disease in Childhood 2008;93(8):660–4.
Christian P, Jiang T, Khatry SK, LeClerq SC, Shrestha SR,
West Jr KP. Antenatal supplementation with micronutrients
and biochemical indicators of status and subclinical
infection in rural Nepal. American Journal of Clinical
Nutrition 2006;83:788–94.
∗ Christian P, Khatry SK, Katz J, Pradhan EK, LeClerq
SC, Shrestha SR, et al. Effects of alternative maternal
micronutrient supplements on low birth weight in rural
Nepal: double blind randomised community trial. BMJ
2003;326(7389):571.
Christian P, Khatry SK, LeClerq SC, Dali SM. Effects of
prenatal micronutrient supplementation on complications
of labor and delivery and puerperal morbidity in rural
Nepal. International Journal of Gynecology & Obstetrics
2009;106(1):3–7.
Christian P, Shrestha J, LeClerq SC, Khatry SK, Jiang T,
Wagner T, et al. Supplementation with micronutrients in
addition to iron and folic acid does not further improve
the hematologic status of pregnant women in rural Nepal.
Journal of Nutrition 2003;133(11):3492–8.
Christian P, Stewart CP, LeClerq SC, Wu L, Katz J, West KP
Jr, et al. Antenatal and postnatal iron supplementation and
childhood mortality in rural Nepal: a prospective follow-
up in a randomized, controlled community trial. American
Journal of Epidemiology 2009;170(9):1127–36.
Katz J, Christian P, Dominici F, Zeger SL. Treatment
effects of maternal micronutrient supplementation vary by
percentiles of the birth weight distribution in rural Nepal.
Journal of Nutrition 2006;136(5):1389–94.
Stewart CP, Christian P, Schulze KJ, Leclerq SC, West KP
Jr, Khatry SK. Antenatal micronutrient supplementation
reduces metabolic syndrome in 6- to 8-year-old children in
rural Nepal. Journal of Nutrition 2009;139(8):1575–81.
Darboe 2007 {published data only}
Darboe MK, Thurnham DI, Morgan G, Adegbola
RA, Secka O, Solon JA, et al. Effectiveness of an early
supplementation scheme of high-dose vitamin A versus
standard WHO protocol in Gambian mothers and infants:
a randomised controlled trial. Lancet 2007;369(9579):
2088–96.
Haskell 2005 {published data only}
Graham JM, Haskell MJ, Pandey P, Shrestha RK, Brown
KH, Allen LH. Supplementation with iron and riboflavin
enhances dark adaptation response to vitamin A-fortified
rice in iron-deficient, pregnant, nightblind Nepali women.
American Journal of Clinical Nutrition 2007;85(5):1375–84.
∗ Haskell MJ, Pandey P, Graham JM, Peerson JM, Shrestha
RK, Brown KH. Recovery from impaired dark adaptation
in nightblind pregnant Nepali women who receive small
daily doses of vitamin A as amaranth leaves, carrots, goat
liver, vitamin A-fortified rice, or retinyl palmitate. American
Journal of Clinical Nutrition 2005;81:461–71.
Howells 1986 {published data only}
Howells DW, Haste F, Rosenberg D, Brown IR, Brooke
OG. Investigation of vitamin a nutrition in pregnant
British Asians and their infants. Human Nutrition. Clinical
Nutrition 1986;40(1):43–50.
Humphrey 2006 {published data only}
Humphrey JH, Iliff PJ, Marinda ET, Mutasa K, Moulton
LH, Chidawanyika H, et al. Effects of a single large dose
of vitamin A, given during the postpartum period to HIV-
positive women and their infants, on child HIV infection,
HIV-free survival, and mortality. Journal of Infectious
Diseases 2006;193(6):860–71.
Laitinen 2009 {published data only}
Laitinen K, Isolauri E, Kaipiainen L, Gylling H, Miettinen
TA. Plant stanol ester spreads as components of a balanced
diet for pregnant and breast-feeding women: evaluation of
clinical safety. British Journal of Nutrition 2009;101(12):
1797–804.
Lietz 2001 {published data only}
∗ Lietz G, Henry CJK, Mulokozi G, Mugyabuso JKL,
Ballart A, Ndossi GD, et al. Comparison of the effects of
supplemental red palm oil and sunflower oil on maternal
vitamin A status. American Journal of Clinical Nutrition
2001;74(4):501–9.
Lietz G, Mulokozi G, Henry JC, Tomkins AM. Xanthophyll
and hydrocarbon carotenoid patterns differ in plasma and
breast milk of women supplemented with red palm oil
during pregnancy and lactation. Journal of Nutrition 2006;
136(7):1821–7.
Roberfroid 2010 {published data only}
Roberfroid D, Huybregts L, Lanou H, Henry MC, Meda
N, Kolsteren P. Effect of maternal multiple micronutrient
supplements on cord blood hormones: a randomized
controlled trial. American Journal of Clinical Nutrition
2010;91:1649–58.
Roy 1997 {published data only}
Roy SK, Islam A, Molla A, Akramuzzaman SM, Jahan
F, Fuchs G. Impact of a single megadose of vitamin a at
delivery on breastmilk of mothers and morbidity of their
infants. European Journal of Clinical Nutrition 1997;51(5):
302–7.
Sharma 2003 {published data only}
Sharma JB, Kumar A, Malhotra M, Arora R, Prasad S, Batra
S. Effect of lycopene on pre-eclampsia and intra-uterine
growth retardation in primigravidas. International Journal
of Gynecology and Obstetrics 2003;81:257–62.
Van Vliet 2001 {published data only}
Van Vliet T, Boelsma E, De Vries AJ, Van den Berg H.
Retinoic acid metabolites in plasma are higher after intake
of liver paste compared with a vitamin a supplement in
women. Journal of Nutrition 2001;131(12):3197–203.
References to ongoing studies
30Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ahmad 2009 {published data only}
Ahmad SM. Vitamin A and maternal-infant flu vaccine
response. ClinicalTrials.gov (http://clinicaltrials.gov/)
[accessed 1 November 2014] 2009.
Additional references
AIDS Report 2008
World Health Organization. 2008 Report on
the global AIDS epidemic. Status of global HIV
epidemic (http://whqlibdoc.who.int/unaids/2008/
9789291737116˙eng˙Chapter2A.pdf). Geneva: World
Health Organization, 2008:29–51.
Angeles-Agdeppa 1997
Angeles-Agdeppa I, Schultink W, Sastroamidjojo S, Gross
R, Karyadi D. Weekly micronutrient supplements to build
iron stores in female Indonesian adolescents. American
Journal of Clinical Nutrition 1997;66:177–83.
Arsenault 2010
Arsenault JE, Aboud S, Manji KP, Fawzi WW, Villamor
E. Vitamin supplementation increases risk of subclinical
mastitis in HIV-infected women. Journal of Nutrition 2010;
140(10):1788–92.
Bloem 1990
Bloem MW, Wedel M, Van Agtmaal EJ, Speek AJ,
Soawakontha S, Schreurs WHP. Vitamin A intervention:
short term effects of a single oral massive dose on iron
metabolism. American Journal of Clinical Nutrition 1990;
51:76–9.
Borel 2005
Borel P, Drai J, Faure H. Recent knowledge about intestinal
absorption and cleavage of carotenoids. Annales de Biologie
Clinique 2005;63(2):165–77.
Christian 2011
Christian P, Labrique AB, Ali H, Richman MJ, Wu
L, Rashid M, et al. Maternal vitamin A and beta-
carotene supplementation and risk of bacterial vaginosis: a
randomized controlled trial in rural Bangladesh. American
Journal of Clinical Nutrition 2011;94(6):1643–9.
Christian 2013
Christian P, Klemm R, Shamim AA, Ali H, Rashid M,
Shaikh S, et al. Effects of vitamin A and beta-carotene
supplementation on birth size and length of gestation in
rural Bangladesh: a cluster-randomized trial. American
Journal of Clinical Nutrition 2013;97(1):188–94.
Combs 2008
Combs GF. The Vitamins: Fundamental Aspects in Nutrition
and Health. 3rd Edition. Burlington: Elsevier Academic
Press, 2008.
Cox 2006
Cox SE, Arthur P, Kirkwood BR. Vitamin A
supplementation increases ratios of pro-inflammatory to
anti-inflammatory cytokine responses in pregnancy and
lactation. Clinical & Experimental Immunology 2006;144
(3):392–400.
Darlow 2007
Darlow BA, Graham PJ. Vitamin A supplementation to
prevent mortality and short- and long-term morbidity
in very low birthweight infants. Cochrane Database of
Systematic Reviews 2011, Issue 10. [DOI: 10.1002/
14651858.CD000501.pub3]
Dijkhuizen 2001
Dijkhuizen MA. Vitamin A, Iron and Zinc Deficiency
in Indonesia. Micronutrient Interactions and Effects of
Supplementation [thesis]. Wageningen University, 2001.
DRI 2001
Institute of Medicine. Dietary Reference Intakes for Vitamin
A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine,
Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium,
and Zinc. Washington, DC: National Academy Press, 2001.
Edmond 2012
Edmond K, Hurt L, Fenty J, Amenga-Etego S, Zandoh
C, Hurt C, et al. Effect of vitamin A supplementation in
women of reproductive age on cause-specific early and late
infant mortality in rural Ghana: ObaapaVitA double-blind,
cluster-randomised, placebo-controlled trial. BMJ Open
2012;2(1):e000658.
FAO and WHO 2002
FAO, WHO 2002. Vitamin A. Human Vitamin and
Mineral Requirements: Report of a Joint FAO/WHO Expert
Consultation Bangkok, Thailand. Rome: WHO, 2002:
87–107.
Fawzi 1993
Fawzi WW, Chalmers TC, Herrera MG, Mosteller F.
Vitamin A supplementation and child mortality. A meta-
analysis. JAMA 1993;269(7):898–903.
FNB 2001
Food, Nutrition Board. Dietary Reference Intakes.
Washington DC: National Academy Press, 2001.
Glasziou 1993
Glasziou PP, Mackerras DE. Vitamin A supplementation
in infectious diseases: a meta-analysis. BMJ 1993;306:
366–70.
Haider 2008
Haider BA, Bhutta ZA. Multiple-micronutrient
supplementation for women during pregnancy. Cochrane
Database of Systematic Reviews 2012, Issue 11. [DOI:
10.1002/14651858.CD004905.pub3]
HAP 2008
Health in Asia and the Pacific. Mortality.
http://www.wpro.who.int/NR/rdonlyres/
3156FAEA-AE96-4C3D-ADF9-302C5831A618/0/
10˙Chapter5Mortality.pdf (accessed 2008).
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
31Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hodges 1978
Hodges RE, Sauberlich HE, Canham JE, Wallace DL,
Rucker RB, Meija LA, et al. Hematopoietic studies in
vitamin A deficiency. American Journal of Clinical Nutrition
1978;31:876–85.
Hurt 2013
Hurt L, Ten Asbroek A, Amenga-Etego S, Zandoh C, Danso
S, Edmond K, et al. Effect of vitamin A supplementation
on cause-specific mortality in women of reproductive age
in Ghana: a secondary analysis from the ObaapaVitA trial.
Bulletin of the World Health Organization 2013;91(1):
19–27.
ICD-10 2007
World Health Organization. International classification of
diseases and related heath problems. 10th revision. Version
for 2007. http://apps.who.int/classifications/apps/icd/
icd10online/ (accessed June 2010).
IMCI- TAG 2008
World Health Organization. Technical Advisory Group on
IMCI (IMCI-TAG). Integrated Management in the Context
of the Maternal-Newborn-Child Health Continuum.
Report of the Fifth Meeting; Texas Children’s Hospital;
2006 May 16-17; Houston, Texas, USA. Washington: Pan
American Health Organization, 2008.
Karyadi 1996
Karyadi D, Bloem MW. The role of vitamin A deficiency in
iron deficiency anaemia and implications for interventions.
Biomedical and Environmental Sciences 1996;9:316–24.
Lidén 2006
Lidén M, Eriksson U. Understanding retinol metabolism:
structure and function of retinol dehydrogenases. Journal of
Biological Chemistry 2006;281(19):13001–4.
Long 2007
Long KZ, Rosado JL, DuPont HL. Supplementation
with vitamin A reduces watery diarrhoea and respiratory
infections in Mexican children. British Journal of Nutrition
2007;97(2):337–43.
Mahalanabis 1979
Mahalanabis D, Simpson TN, Chakraborty ML, Ganguli
C, Bhattacharjee AK, Mukherjee KL. Malabsorption of
water miscible vitamin A in children with giardiasis and
ascariasis. American Journal of Clinical Nutrition 1979;32:
313–8.
McGuire 2007
McGuire M, Beerman KA. Nutritional Sciences: From
Fundamentals to Food. 1st Edition. Belmont, CA:
Thomson/Wadsworth, 2007.
Mejia 1977
Mejia LA, Hodges RE, Arroyave G. Vitamin A deficiency
and anaemia in Central American children. American
Journal of Clinical Nutrition 1977;30:1175–84.
Mejia 1982
Mejia LA, Arroyave G. The effect of vitamin A fortification
of sugar on iron metabolism in preschool children in
Guatemala. American Journal of Clinical Nutrition 1982;36
(1):87–93. [PUBMED: 7091038]
Mejia 1988
Mejia LA, Chew F. Hematological effect of supplementing
anemic children with vitamin A alone and in combination
with iron. American Journal of Clinical Nutrition 1988;48:
595–600.
Miller 1998
Miller RK, Hendrckx AG, Mills JL, Hummler H, Wiegand
UW. Periconceptional vitamin A use: how much is
teratogenic?. Reproductive Toxicology 1998;12(1):75–88.
Mills 1997
Mills JL, Simpson JL, Cunningham GC, Conley MA,
Rhoads GG. Vitamin A and birth defects. American Journal
of Obstetrics and Gynecology 1997;177:31–6.
Moffa 1970
Moffa DJ, Lotspeich FJ, Krause RF. Preparation and
properties of retinal-oxidizing enzyme from rat intestinal
mucosa. Journal of Biological Chemistry 1970;245:439–47.
Muhilal 1988
Muhilal, Permeisih D, Idjradinata YR. Vitamin A fortified
monosodium glutamate and health, growth and survival
of children: a controlled field trial. American Journal of
Clinical Nutrition 1988;48:1271–6.
NCCWCH 2008
National Collaborating Centre for Women’s and Children’s
Health. Antenatal Care: Routine Care for the Healthy
Pregnant Woman. London: RCOG Press, 2008.
Oliveira 2010
Oliveira-Menegozzo JM, Bergamaschi DP, Middleton
P, East CE. Vitamin A supplementation for postpartum
women. Cochrane Database of Systematic Reviews 2010,
Issue 10. [DOI: 10.1002/14651858.CD005944.pub2]
Olofin 2014
Olofin IO, Spiegelman D, Aboud S, Duggan C, Danaei
G, Fawzi WW. Supplementation with multivitamins and
vitamin A and incidence of malaria among HIV-infected
Tanzanian women. Journal of Acquired Immune Deficiency
Syndromes 2014;67(Suppl 4):S173–8.
PNM 2005
World Health Organization. Perinatal and Neonatal
Mortality. Geneva: World Health Organization, 2005.
Prawirohartono 2011
Prawirohartono EP, Nystrom L, Ivarsson A, Stenlund
H, Lind T. The impact of prenatal vitamin A and zinc
supplementation on growth of children up to 2 years of age
in rural Java, Indonesia. Public Health Nutrition 2011;14
(12):2197–206.
Prawirohartono 2013
Prawirohartono EP, Nystrom L, Nurdiati DS, Hakimi
M, Lind T. The impact of prenatal vitamin A and zinc
supplementation on birth size and neonatal survival - a
double-blind, randomized controlled trial in a rural area of
Indonesia. International Journal for Vitamin and Nutrition
Research 2013;83(1):14–25.
32Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RevMan 2014
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.3. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.
Ross 1994
Ross AC, Gardner EM. The function of vitamin A in
cellular growth and differentiation, and its roles during
pregnancy and lactation. Advances in Experimental Medicine
and Biology 1994;352:187–200.
Rothman 1995
Rothman KJ, Moore LL, Singer MR, Nguyen UDT,
Mannino S, Milunsky A. Teratogenecity of high Vitamin
A intake. New England Journal of Medicine 1995;333:
1367–73.
Rousseau 1992
Rousseau EJ, Davison AJ, Dunn B. Protection by
beta-carotene and related compounds against oxygen-
mediated cytotoxicity and genotoxicity: implications for
carcinogenesis and anticarcinogenesis. Free Radical Biology
and Medicine 1992;13:407–33.
Semba 2000
Semba RD, Kumwenda N, Taha TE, Mtimavalye L,
Broadhead R, Miotti PG, et al. Plasma and breast milk
vitamin A as indicators of vitamin A status in pregnant
women. International Journal for Vitamin and Nutrition
Research 2000;70(6):271–7.
Sivakumar 1972
Sivakumar B, Reddy V. Absorption of labelled vitamin A in
children during infection. British Journal of Nutrition 1972;
27:297–304.
Sommer 1982
Sommer A. Nutritional Blindness. Xerophthalmia and
Keratomalacia. 1st Edition. New York: Oxford University
Press, 1982.
Sommer 1995
Sommer A. Vitamin A Deficiency and its Consequences: a
Field Guide to Detection and Control. 3rd Edition. Geneva:
World Health Organization, 1995.
Stephens 1996
Stephens D, Jackson PL, Gutierrez Y. Subclinical vitamin
A deficiency: a potentially unrecognized problem in the
United States. Pediatric Nursing 1996;22(5):377–89.
Stipanuk 2006
Stipanuk MH. Biochemical, Physiological and Molecular
Aspects of Human Nutrition. 2nd Edition. Philadelphia:
Saunders, 2006.
Suharno 1992
Suharno D, West CE, Muhilal, Logman MHGM, De
Waart FG, Karyadi D, et al. Cross-sectional study on the
iron and Vitamin A status of pregnant women in West Java,
Indonesia. American Journal of Clinical Nutrition 1992;56:
988–93.
Tang 2005
Tang G, Qin J, Dolnikowski GG, Russell RM, Grusak
MA. Spinach or carrots can supply significant amounts of
vitamin A as assessed by feeding with intrinsically deuterated
vegetables. American Journal of Clinical Nutrition 2005;82
(4):821–8.
Thurnham 1989
Thurnham DI. Vitamin A deficiency and its role in
infection. Transactions of the Royal Society of Tropical Hygiene
and Medicine 1989;83:721–3.
Tomkins 1989
Tomkins A, Hussey G. Vitamin A, immunity and infection.
Nutrition Research Reviews 1989;2:17–28.
Underwood 1990
Underwood BA. Methods for assessment of vitamin A
status. Journal of Nutrition 1990;120:1459–63.
Underwood 1994
Underwood BA. Maternal vitamin A status and its
importance in infancy and early childhood. American
Journal of Clinical Nutrition 1994;59:517S–522S.
Van den Broek 1998
Van den Broek N. Anaemia in pregnancy in developing
countries. British Journal of Obstetrics and Gynaecology
1998;105:385–90.
Van den Broek 2000
Van den Broek NR, Letsky EA. Etiology of anemia in south
Malawi. American Journal of Clinical Nutrition 2000;72(1):
247S–256S.
Von Lintig 2000
Von Lintig J, Vogt K. Filling the gap in vitamin A research:
molecular identification of an enzyme cleaving beta-
carotene to retinal. Journal of Biological Chemistry 2000;275
(16):11915–20.
WHO 1995
World Health Organization. Global Prevalence of Vitamin
A Deficiency. Micronutrient Deficiency Information System
(WHO/NUT/95). Geneva: WHO, 1995.
WHO 1996
World Health Organization. Indicators for assessing vitamin
A deficiency and their application in monitoring and evaluating
intervention programmes. 1st Edition. Geneva: World
Health Organization, 1996:66.
WHO 1998
World Health Organization. Safe vitamin A dosage during
pregnancy and lactation. Recommendations and report of
a consultation. Geneva: WHO (WHO/NUT/98), 1998.
Geneva: WHO, 1998.
WHR 2005
World Health Organization. The World Health Report
2005 - make every mother and child count. http://
www.who.int/whr/2005/en/ (accessed June 2010) 2005.
Wiysonge 2011
Wiysonge CS, Shey M, Kongnyuy EJ, Sterne JAC,
Brocklehurst P. Vitamin A supplementation for reducing
the risk of mother-to-child transmission of HIV infection.
Cochrane Database of Systematic Reviews 2011, Issue 1.
[DOI: 10.1002/14651858.CD003648.pub3]
33Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wolde-Gabriel 1993
Wolde-Gabriel Z, West CE, Speek AJ. Interrelationship
between Vitamin A, iodine and iron status in school
children in the Shoa Region - Central Ethiopia. British
Journal of Nutrition 1993; Vol. 70:593–607.
References to other published versions of this review
Van den Broek 2002
Van den Broek N, Kulier R, Gülmezoglu AM, Villar J.
Vitamin A supplementation during pregnancy. Cochrane
Database of Systematic Reviews 2002, Issue 4. [DOI:
10.1002/14651858.CD001996]
van den Broek 2010
van den Broek N, Dou L, Othman M, Neilson JP, Gates
S, Gülmezoglu AM. Vitamin A supplementation during
pregnancy for maternal and newborn outcomes. Cochrane
Database of Systematic Reviews 2010, Issue 11. [DOI:
10.1002/14651858.CD008666.pub2]
∗ Indicates the major publication for the study
34Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ajans 1965
Methods RCT.
Participants Inclusion criteria: 44 parturient women in good health from the lower and middle
socioeconomic groups (in a population in which vitamin A deficiency occurs)
Interventions Intervention group 1: 15 women.
Single intramuscular injection of 600,000 lU of vitamin A palmitate in oil at parturi-
tion. 4 samples of 2 to 3 mL of colostrum were collected. 1 antepartum sample and 3
postpartum samples, 1 on each consecutive day of hospitalisation
Intervention group 2: 11 women.
Given 600,000 lU of water-dispersible vitamin A palmitate orally shortly before deliv-
ery. 4 samples of 2 to 3 mL of colostrum were collected. 1 antepartum sample and 3
postpartum samples, 1 on each consecutive day of hospitalisation. Followed by public
health nurses at their homes where bi-weekly samples of milk were collected during the
first week after discharge and then weekly samples for a total period ranging between 38
and 59 days postpartum
Control group: 18womennot given any formof vitamin A therapy prepartum. 4 samples
of 2 to 3 mL of colostrum were collected. 1 antepartum sample and 3 postpartum
samples, 1 on each consecutive day of hospitalisation
Outcomes Primary outcome: levels of vitamin A and carotenoids in the maternal blood. Other
outcomes: levels of vitamin A and carotenoids in the colostrum prenatal and postnatal
Notes Vitamin A levels measured before starting supplementation in group 1 and 2
Study was done in a population in which vitamin A deficiency occurs
Study setting: American university hospital.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description except allotted at random.
Allocation concealment (selection bias) Unclear risk No description except allotted at random.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding methods were reported. The routes of medication
administration methods varied across groups
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided.
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Ajans 1965 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusion or loss of follow-up reported.
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias High risk The 3 groups were not studied during the same period. The
authors reported “subjects in groups 1 and 2 were studied in the
summer and those of group 3 in the following winter”
Coutsoudis 1999
Methods Double-blind RCT.
Participants Inclusion criteria:
• pregnant women 28-32 weeks’ gestation;
• HIV-positive.
(HIV-seropositive women identified through antenatal screening programmes. All the
women enrolled were black Africans.)
Interventions Intervention group: 368 women received daily dose of 5000 IU retinyl palmitate and
30 mg beta-carotene during the third trimester of pregnancy (together corresponding to
43,400 IU vitamin A daily for 12 weeks) and 200,000 IU retinyl palmitate at delivery
Control group: 360 women received placebo on the same schedule
Outcomes Primary outcome: effects of vitamin A on HIV viral load and HIV transmission
Other outcomes: neonatal mortality (the number of deaths during the first 28 completed
days of life per 1000 live births in a given year or period) and anaemia, maternal anaemia,
clinical infection (fever > 1 week at 1 week postnatally), preterm birth (delivery less
than 37 completed weeks’ gestational age estimated using LMP), low birthweight and
morbidity
Notes Vitamin A levels were measured before starting supplementation
Country: South Africa.
Study setting: King Edward VIII Hospital and McCords Hospital, in Durban, South
Africa
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided.
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel “double-blind”.
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Coutsoudis 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 57 (7.8%) women did not deliver in the hospitals and cannot
be traced
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Low risk No other bias awarded.
Cox 2005
Methods A randomised double-blind controlled trial.
Participants Inclusion criteria:
• primigravid pregnant women;
• resident within the study area;
• in good health;
• less than 24 weeks pregnant.
Exclusion criteria: HIV infection or tuberculosis.
Interventions Intervention group: 48 women received weekly capsules of 10,000 IU of vitamin A as
retinyl palmitate in groundnut oil, plus tocopherol as a preservative from enrolment
until 6 weeks postpartum. Suplimintation was for a minimum of 18 weeks
Control group: 50 women received groundnut oil and tocopherol only in the placebo
capsules from enrolment until 6 weeks postpartum
Outcomes Primary outcome: maternal infections (presence of placental malaria and peripheral
parasitaemia)
Other outcomes: Hb and birthweight.
Notes Vitamin A levels were measured before starting supplementation
Country: Ghana.
Study setting: Nkoranza District Hospital and 3 rural health clinics in Brong Ahafo
region, Central Ghana
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “balanced block randomisation.”
Allocation concealment (selection bias) Unclear risk No information provided.
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Cox 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 (12%) women were excluded from the
analysis: 1 false pregnancy, 1 early miscar-
riage, 10 missed late pregnancy visit
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available
at the moment.
Other bias Unclear risk The most marked difference was in edu-
cational level and gestational age at enrol-
ment. Levels of anti-VSACSA IgG to the
FCR3CSA parasite line differed between
the treatment groups at baseline. There
were considerably fewer data available for
the placebo than the vitamin A group at the
late pregnancy follow-up
Dijkhuizen 2004
Methods Double-blind RCT, factorial design.
Participants Inclusion criteria: all women were recruited before 20 weeks’ gestational age
Exclusion criteria: twin pregnancy and congenital abnormalities that interfered with
growth, development, or metabolism
Interventions Intervention group 1: 37 women received iron and folic acid supplements together with
ß -carotene (4.5 mg as water-soluble granulate/d (representing 5750 IU of vitamin A))
. Each woman was supplemented daily during pregnancy until delivery for a minimum
of 16 weeks
Intervention group 2: 37 women received iron and folic acid supplements together with
zinc (30 mg zinc as sulphate/d). Each woman was supplemented daily during pregnancy
until delivery
Intervention group 3: 37 women received iron and folic acid supplements together with
zinc and carotene. Each woman was supplemented daily during pregnancy until delivery
Control group: 37 women received iron and folic acid.
Outcomes Primary outcome: maternal and fetal Hb and zinc levels.
Other outcomes: maternal and fetal ferritin, retinol and carotene levels
Other outcomes from this same trial were recorded by Dijkhuizen 2001- see notes below.
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Dijkhuizen 2004 (Continued)
Notes Vitamin A levels were not measured before starting supplementation
Country: Indonesia.
Study setting: 13 adjacent villages in a rural area in Bogor District, West Java, Indonesia
Dijkhuizen 2001 assessed maternal and neonatal complications in this same trial de-
scribed above. Outcomes described included maternal puerperal fever, preterm delivery,
stillbirth, neonatal mortality and birthweight
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided except factorial ran-
domisation.
Allocation concealment (selection bias) Low risk ”Capsules were indistinguishable and given a let-
ter code.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 35 (20%) women were not followed up or in-
cluded in the analyses
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the
moment.
Other bias Low risk No other bias awarded.
Fawzi 1998
Methods 2-by-2 factorial design.
Participants Inclusion criteria:
• pregnant women 12-27 weeks’ gestation;
• HIV-positive women;
• resident in Dar es Salaam at the time of baseline interview;
• intend to stay in the city until delivery and 1 year breastfeeding thereafter.
Interventions Intervention group 1: 270 women received a daily (for at least 10 weeks) oral dose of
multivitamins including vitamin A (30 mg b-carotene (representing 38,000 IU vitamin
A) and 5000 IU of preformed vitamin A, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100
mg of niacin, 50 mg of B12, 500 mg of C, 30 mg of vitamin E, and 0.8 mg of folic acid)
; an additional oral dose of vitamin A (200,000 IU) at delivery
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Fawzi 1998 (Continued)
Intervention group 2: 269 women received a daily oral dose of vitamin A alone (30 mg
b-carotene and 5000 IU of preformed vitamin A), plus an additional oral dose of vitamin
A (200,000 IU) at delivery
Intervention group 3: 269 women received a daily oral dose of multivitamins excluding
vitamin A, plus an additional oral placebo at delivery
Intervention group 4: 267 women received a daily oral dose of placebo. An additional
oral placebo at delivery
Outcomes Primary outcome: CD levels in both mother and fetus and HIV transmission
Other outcomes: birthweight, preterm birth (delivery less than 37 completed weeks
estimated using LMP) and Hb in both mother and fetus (Hb < 10.0 g/dL)
Notes Vitamin A levels were measured before starting supplementation
Country: Tanzania.
Duration: 1995-1997.
Study setting: 4 ANCs with several smaller peripheral clinics
Other secondary outcomes of interest in this review (maternal infection) from this trial
are described by Arsenault 2010 and Olofin 2014.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomisation was done in blocks of 20.”
Allocation concealment (selection bias) Low risk “At enrolment, we assigned each eligiblewomen the next num-
bered bottle of regimen.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel “double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 117 (10.8%) women were excluded from the analysis:
• 3 not pregnant;
• 7 died before delivery and excluded;
• 54 lost to follow-up;
• 53 no date of delivery or gestational age.
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Low risk No other bias awarded.
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Green 1931
Methods Quasi-RCT, multi-centred.
Participants Inclusion criteria: pregnant women.
Exclusion criteria: cases not delivered in hospital.
Interventions Intervention group: 275 women received 1 oz of the vitamin preparation radiostoleum,
an amount equivalent in vitamins A and D roughly to 30 oz of a good cod-liver oil
(equivalent to 444,000 IU vitamin A), should have been taken daily commencing 1
month previous to the calculated day of labour
The first 76 cases prior to June 1929 were given the preparation for only 14 days before
delivery (daily). It was, however, continued for the first 7 days of the puerperium. It was
thendecided that amore logical procedurewould probably be to begin the administration
earlier and thus build up a larger reserve at the time of labour
Control group: 275 women received an untreated version.
Outcomes Maternal infection (puerperal fever > 38o C) and maternal and baby mortality and
morbidity.
Notes Vitamin A levels were not measured before starting supplementation
Country: UK.
Study setting: the Jessop Hospital and the Nether Edge municipal hospital
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “the first patient was given the preparation and the next
due for delivery about the same time was indexed as a
control.”
Allocation concealment (selection bias) High risk “the first patient was given the preparation and the next
due for delivery about the same time was indexed as a
control.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The control group received no intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 50 (8.3%) women delivered somewhere else and were ex-
cluded.
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Low risk No other bias awarded.
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Hakimi 1999
Methods Randomised, placebo-controlled double masked community-based trial
Participants Inclusion: women with positive pregnancy test in the first 120 days of pregnancy
Exclusion:
• women who were not married or did not have a life partner;
• women whose gestational age > first trimester;
• women using hormonal contraception or intrauterine device;
• peri-menopausal women.
Interventions Group 1: 248 received vitamin A 2400 retinol equivalent, second group 254 received
zinc 20 mg/day, third group 243 received both vitamin A and zinc, while the fourth
group 263 received placebo
Outcomes Maternal sepsis (temp 38oC between day 2-14 postpartum), haemorrhage (bleeding
during labour or within 2 days of delivery)
Notes Trial run between 1995 and 1997 in Indonesia termed the ZIBUVITA trial
Setting: Central Java, Indonesia.
Of note this study information is from a draft of a publication which was not published
in any peer review journal
However, 2 follow-up studies using this original trial have been published,
Prawirohartono 2011 and Prawirohartono 2013.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “1:1:1:1 ratio in blocks of 12 based on a
list of treatment numbers derived from a
pseudo-random number generator in SAS.
”
Allocation concealment (selection bias) Low risk “treatment allocation sequence was pre-
pared and held at ..a site remote from the
trial.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “supplements were packaged in ..identical
opaque pink capsules.”
“all investigators, field and laboratory staff
and participants were blinded to the treat-
ment code.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “a survey of sample of field workers and
their supervisors revealed they were unable
to identify which treatments the study par-
ticipants were receiving.”
Incomplete outcome data (attrition bias)
All outcomes
High risk > 20% loss to follow-up.
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Hakimi 1999 (Continued)
Selective reporting (reporting bias) Unclear risk The protocol of this study is not available.
Other bias High risk Of note this information is from a draft of
a publication which was not published in
any peer review journal. However, 2 fol-
low-up studies using this original trial have
been published, Prawirohartono 2011 and
Prawirohartono 2013.
Kirkwood 2010
Methods Cluster-randomised trial.
Participants Inclusion criteria: women aged 15 to 45 years giving informed consent and who planned
to live in the trial area for at least 3 months were eligible for enrolment
Interventions Intervention group: 104,484 women in 544 clusters received weekly vitamin A capsule
consisted of 25,000 IU (7500 ug) retinol equivalents (equivalent to 25,000 IU vitamin
A) in soybean oil in a dark red opaque soft gel for 12 weeks
Control group: 103,297 women in 542 clusters received placebo capsule consisted of
soybean oil only
Outcomes Primary outcome: maternal mortality and all-cause female mortality
Other outcomes: maternal morbidity, perinatal and neonatal mortality (the number of
deaths during the first 28 completed days of life per 1000 live births in a given year or
period)
Notes Setting: 7 districts in Brong Ahafo region in Ghana.
Sample size: more that 207,000 pregnant women.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated randomisation list.”
Allocation concealment (selection bias) Low risk “The capsules were packaged in labelled jars.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel “Double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
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Kirkwood 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 44% of enrolled women initially reported as loss to follow-
up: 1% withdrew consent, 43% moved. However, supple-
mentary information provided by authors in February 2011
at the time of more detailed analysis reported overall loss to
follow-up for analysis for pregnancy-related mortality anal-
ysis as 8%: 4657 pregnancies excluded because outcome not
known (with 2340 in vitamin A arm and 2317 in placebo
arm). 4192 pregnancies excluded because status of woman
at 42 days not known (2174 vitamin A; 2018 placebo). Be-
fore these exclusions, the total number of pregnancies cap-
tured was 111,801; after exclusions, the total number of
pregnancies with a known outcome was 102,952
Selective reporting (reporting bias) Unclear risk The study protocol is not available.
Other bias Low risk No other bias awarded.
Kumwenda 2002
Methods RCT.
Participants Inclusion criteria:
• pregnant women of 18-28 weeks’ gestation;
• HIV-positive women.
Interventions Intervention group: 340 women received daily doses of orally administered vitamin A
(3 mg retinol equivalent (10,000 IU of vitamin A) + iron and folate for minimum of 12
weeks. Oral vitamin A (30 mg retinol equivalent) at 6 weeks’ postpartum
Control group: 357 women received daily doses of iron (30 mg of elemental iron) and
folate (400 mg) from the time of study enrolment until delivery. Oral vitamin A (30 mg
retinol equivalent) at 6 weeks postpartum
Outcomes Primary outcome: maternal vitamin A levels in blood and breast milk and HIV trans-
mission in mother and baby
Other outcomes: Hb and birthweight.
Notes Vitamin A levels were measured before starting supplementation
Country: Malawi.
Study setting: Queen Elizabeth Central Hospital (Blantyre, Malawi)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a computer random-number generator.”
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Kumwenda 2002 (Continued)
Allocation concealment (selection bias) Low risk “pre packing study supplements in sequentially numbered series
assigned to study identification numbers.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel “Double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 63 (9%) women were excluded from the analysis: 57 moved out,
6 could not be located
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Low risk Not aware of any other bias.
Muslimatun 2001
Methods A randomised double-blind community-based trial.
Participants Inclusion criteria: 16 to 20 weeks pregnant, aged 17-35 years and parity < 6
Interventions Intervention group: 122 women received each week from enrolment until delivery 2
tablets each ofwhich contained 3000REvitaminA in addition to the ferrous sulphate and
folic acid. So intervention was 6000 RE vitamin A (20,000 IU) weekly for a minimum
of 16 weeks
Control group: 121 women received each week from enrolment until delivery 2 tablets
each containing 60 mg elemental iron as ferrous sulphate and 250 mg folic acid
Outcomes Primary outcome: infant growth in 1 year of life.
Other outcomes: maternal Hb and fetal morbidity.
Notes Vitamin A levels were measured before starting supplementation
Country: Indonesia.
Study setting: 9 villages in the rural subdistrict of Leuwiliang, West Java, Indonesia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assigned randomly.”
Allocation concealment (selection bias) Unclear risk No information provided.
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Muslimatun 2001 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants andpersonnel “Double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Out of 243 pregnant women initially en-
rolled, 18 dropped out during pregnancy, 5
gave birth to a stillborn child, 1 had twins
(only 1 survived), 7 had infants who died
before reaching 3 months of age and 11
moved from the research area. Among the
remaining 201 eligible participants, 182
participants attended the postpartum ex-
amination. Overall, the loss to follow-up of
the intervention group was 32.8 % and the
control group was 27.3%
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available
at the moment.
Other bias Low risk Not aware of any other bias.
Radhika 2003
Methods “double-blinded, randomized, controlled study.”
Participants Inclusion criteria:
• 16 and 24 weeks’ gestation;
• willing to have a follow-up every 2 weeks and who resided in the city area were
chosen for the study.
Exclusion criteria: women with recurrent pregnancy loss or earlier preterm delivery and
those with diabetes, hypertension, or any other metabolic disorder
Interventions Intervention group: 85 women received red palm oil providing 2173 to 2307 µg of β-
carotene per day with a dosage schedule of 1 sachet per day (8 mL), which provided 91%
to 96% of the daily requirement of vitamin A in pregnancy, (i.e. 2400 µg of β-carotene
which is equivalent to 3000 IU of vitamin A) daily for a period of 8 weeks
Control group: 85 women received 1 sachet of groundnut oil (8 mL) for a period of 8
weeks
Outcomes Primary outcome: maternal and neonatal vitamin A status.
Other outcomes: Hb levels in mother and baby, preterm birth (delivery less than 37
completed weeks as confirmed by ultrasound examination), birthweight and gestational
age
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Radhika 2003 (Continued)
Notes Vitamin A levels were measured before starting supplementation
Country: India.
Study setting: the outpatient department of Niloufer Hospital, Hyderabad, India
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided.
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants andpersonnel “Double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 41 (24.1%)womenwere excluded from the
analysis: 23 were not available for supple-
mentation, while 18 dropped out after ini-
tiating supplementation
Overall, the loss to follow-up of the inter-
vention group was 9.5 % and the control
group was 15.1%
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available
at the moment.
Other bias Low risk No other bias awarded.
Semba 2001
Methods A randomised, double-blind, controlled clinical trial.
Participants Inclusion criteria:
• pregnant women;
• 18-28 weeks’ gestation;
• HIV-negative women.
Interventions Intervention group: 109 women received daily supplement containing iron (30 mg
elemental iron), folate (400 mg), and vitamin A (3000 µg retinol equivalent, which is
10,000 IU of vitamin A) until delivery for a minimum of 8 weeks
Control group: 94 women received daily supplement containing iron (30 mg) and folate
(400 mg) until delivery
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Semba 2001 (Continued)
Outcomes Primary outcome: Hb concentrations and plasma erythropoietin concentrations
Other outcomes: levels of ferritin, ? 1-acid glycoprotein, CRP and plasma vitamin A
Notes Vitamin A levels were measured before starting supplementation
Country: Malawi.
Study setting: the Queen Elizabeth Central Hospital in Blantyre, Malawi
Semba 2001 is linked to the Semba 2000 trial; the difference being that Semba 2000
investigated slightly different outcomes inHIV-positivewomen andSemba 2001 assessed
HIV negative women.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a computer random-number generator.”
Allocation concealment (selection bias) Low risk “sequentially numbered opaque bottle.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants andpersonnel “Double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
High risk 66 (32.5%)womenwere excluded from the
analysis: 42missed the study visit, 9 did not
have their Hb analysed, 15 moved out
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available
at the moment.
Other bias Low risk No other bias awarded.
Suharno 1993
Methods Double-blinded RCT.
Participants Inclusion criteria:
• middle and low socioeconomic;
• 16-24 weeks pregnant;
• 17-35 years old;
• parity 0-4;
• Hb 80-109 g/L.
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Suharno 1993 (Continued)
Interventions Intervention group 1: 63 women received vitamin A (2.4 mg retinol as retinyl palmitate)
(equivalent to 8000 IU of vitamin A) and placebo iron tablets daily for 8 weeks
Intervention group 2: 63 women received iron tablets (60 mg ferrous sulphate) and
placebo vitamin A daily for 8 weeks
Intervention group 3: 63 women received vitamin A and iron daily for 8 weeks
Control group: 62 women received both placebo daily for 8 weeks
Outcomes Maternal anaemia indices.
Notes Vitamin A levels were measured before starting supplementation
Country: Indonesia.
Study setting: rural villages in 3 subdistricts of Bogo, West Java
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly.”
Allocation concealment (selection bias) Low risk ’An independent researcher randomly labelled’ the preparations
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel “Double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 54 (17%) women were excluded from the analysis: 11 moved,
23 taken supplement less than 8 weeks, 10 refused blood sam-
ple, 10 not available for 2nd blood sample.
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Low risk No other bias awarded.
Sun 2010
Methods Double-blind RCT.
Participants Inclusion criteria:
• anaemic (Hb > 80 but < 110g/L);
• pregnant women, 12-24 weeks’ gestation, age between 20-30 years;
• no dietary supplements during previous 2 months;
• no abnormal pregnancy response.
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Sun 2010 (Continued)
Interventions 4 groups:
• group 1 (n = 47) was supplemented daily with 60 mg iron as ferrous sulphate;
• group 2 (n = 46) with 60 mg and 0.4 mg folic acid;
• group 3 (n = 46) with 60 mg iron, 2.0 mg retinol and 0.4 mg folic acid;
• group 4 (n = 47) was the placebo control group.
Outcomes Primary outcomes:
• iron status;
• Cytokine Interleukin -2 (IL -2) levels;
• Lymphocyte proliferation.
Notes Short intervention time of 2 months duration.
Patient were recruited between March 2004 - September 2005.
Setting: Shen county in a central rural area of China.
Total number of patients - 186.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Patients were randomised in order of enrolment.”
Allocation concealment (selection bias) High risk “Patients were randomised in order of enrolment.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Adequate blinding of participants and personnel reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss of participants < 5% - 6 women did not complete the
trial due to moving to other villages (3), and stopped taking
supplements during the trial (3)
Selective reporting (reporting bias) Unclear risk No details given.
Other bias Unclear risk No details given.
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Suprapto 2002
Methods Quasi-RCT. A double-blind, placebo, controlled trial.
Participants Inclusion criteria:
• aged less than 35 years;
• between 13 and 28 weeks’ gestation;
• single pregnancy;
• in good health;
• anaemia (Hb < 11.0 g/dL).
Exclusion criteria:
• pregnant women with pre-eclampsia, congestive heart disease, tuberculosis and
acute infections;
• women in the first trimester of pregnancy.
Interventions Intervention group 1: 22women; group IFR received iron-folate tablets + 5mg riboflavin
7 days a week for 60 days
Intervention group 2: 29 women; group IFA received iron-folate tablets + 2.75mg retinyl
palmitate (equal to 5000 IU vitamin A) 7 days a week for 60 days
Intervention group 3: 23 women; group IFRA received iron-folate tablets + 5 mg ri-
boflavin + 2.75 mg retinyl palmitate 7 days a week for 60 days
Control group: 29 women; group IF received iron-folate tablets + 5 mg glucose 7 days
a week for 60 days
Outcomes Maternal levels of vitamin A and riboflavin.
Notes Vitamin A levels were measured before starting supplementation
Country: Indonesia.
Study setting: health centre ANC.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “allocated alternately.”
Allocation concealment (selection bias) High risk “allocated alternately.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “participants and personnel double-blind.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19 (18.4%) were excluded from the analy-
ses: 9 premature labour, 1 stillbirth, 1 mi-
gration, 1 refusal to give blood, 2 nausea
and vomiting and 5 incorrect dates given
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Suprapto 2002 (Continued)
for last menstruation but with normal de-
liveries
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available
at the moment.
Other bias High risk Women in group IFRA were shorter and
lighter than those in other groups
Tanumihardjo 2002
Methods RCT.
Participants Inclusion criteria:
• pregnant women in the second or early third trimester;
• 18 to 37 years old;
• parity from 0 to 4 children.
Interventions Intervention group 1: 5 women received 1.07 mmol (60 mg) ferrous sulphate with a
vitamin A placebo daily for 8 weeks
Intervention group 2: 8 women received vitamin A plus iron.
Intervention group 3: 7 women received 8.4 µmol (8000 IU) vitamin A as retinyl palmi-
tate with an iron placebo
Control group: 7 women received placebo.
Outcomes Maternal Hb and retinol levels.
Notes Vitamin A levels were measured before starting supplementation
Country: Indonesia.
Study setting: local health posts the suburban areas of Bogor in West Java
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided.
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects and village volunteers were unaware of group assign-
ment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
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Tanumihardjo 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss of follow-up reported.
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Unclear risk Not enough information provided.
van den Broek 2006
Methods RCT.
Participants Inclusion criteria:
• (Hb) < 11.0 g/dl by HemoCue screening method at first antenatal visit;
• singleton pregnancy with gestational age > 12 weeks and < 24 weeks measured by
ultrasound scan;
• no fetal abnormality detectable by ultrasound at time of booking;
• residing in the catchment area of the health centre;
• signed informed consent.
Exclusion criteria: twin pregnancy.
Interventions Intervention group 1: 234 women; 5000 IU vitamin A and iron tablets daily (60 mg
elemental iron as ferrous sulphate with 0.25 mg folic acid) and antimalarial prophylaxis
as 2 doses of Fansidar (500 mg sulphadoxine with 25 mg pyrimethamine. Tablets given
daily from enrolment till delivery minimum of 8 weeks
Intervention group 2: 234 women; 10,000 IU vitamin A and iron tablets daily (60 mg
elemental iron as ferrous sulphate with 0.25 mg folic acid) and antimalarial prophylaxis
as 2 doses of Fansidar (500 mg sulphadoxine with 25 mg pyrimethamine)
Control group: 232 women; placebo and iron tablets daily (60 mg elemental iron as
ferrous sulphate with 0.25 mg folic acid) and antimalarial prophylaxis as 2 doses of
Fansidar (500 mg sulphadoxine with 25 mg pyrimethamine
Outcomes Primary outcome: Hb concentrations and anaemia.
Other outcomes: iron status, preterm birth (delivery less than 37 completed weeks as
confirmed by ultrasound examination), markers of infections included CRP, malaria
parasitaemia and HIV status
Notes Vitamin A levels were measured before starting supplementation
Country: Malawi.
Study setting: rural southern Malawi attending ANC at Health Centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a random-generation procedure.”
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van den Broek 2006 (Continued)
Allocation concealment (selection bias) Low risk “consecutive numbers” “in sealed envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The supplements in vitaminA andplacebo treatments allocated
were prepared in identical capsules.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The supplements in vitaminA andplacebo treatments allocated
were prepared in identical capsules.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96 (13.7%) women were excluded from the analyses: 18 women
moved out from the area, 68 declined to continue, 10 missed
appointment
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Low risk Not aware of other bias.
West 1999
Methods Double-blind cluster RCT.
Participants Inclusion criteria:
• women of childbearing age who were married and living with their husbands;
• newly married women.
Exclusion criteria: women who were already married who had moved into study wards
Interventions Intervention group 1: 15,305 women in 90 wards received opaque, gelatinous capsules
containing peanut oil and 23,300 IU of preformed vitamin A (7000 µg retinol equiva-
lents) as retinyl palmitate weekly for a minimum of 12 weeks
Intervention group 2: 14,536 women in 90 wards received 42 mg of all trans-b carotene
(7000 µg retinol equivalents, assuming a conversion ratio to retinol of 6 to 1 after uptake)
weekly
Control group: 14,805 women in 90 wards received no vitamin A or b carotene (placebo)
weekly
Outcomes Primary outcome: mortality of mother and baby (the number of deaths during the first
28 completed days of life per 1000 live births in a given year or period)
Other outcomes: maternal vitamin A and retinol levels, and maternal morbidity
Notes Vitamin A levels were not measured before starting supplementation
Country: Nepal.
Study setting: 270 wards in 30 subdistricts.
Risk of bias
Bias Authors’ judgement Support for judgement
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West 1999 (Continued)
Random sequence generation (selection
bias)
Low risk “All wards were assigned in Kathmandu by a random
draw of numbered chits, blocked on subdistrict, for eligi-
ble women to receive one of three identical coded supple-
ments.”
Allocation concealment (selection bias) Low risk “’three identical coded supplements.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel “double-blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details not included.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1136 (2.5%) women were excluded because they emi-
grated before becoming pregnant or dying or because they
declined to be recruited. 157 women were lost to follow-
up during the postpartum period (their median follow-up
time postpartum was around 2 weeks in each group)
Selective reporting (reporting bias) Unclear risk The protocol of the study is not available at the moment.
Other bias Low risk No other bias awarded.
West 2011
Methods Double-blind cluster-randomised placebo-controlled trial.
Participants Inclusion criteria:
all married women of reproductive age (13-45 years of age) were under surveillance living
in the study settings and all who became pregnant were included in this study
Exclusion criteria:
> first trimester of pregnancy;
women who during surveillance:
• permanently moved outside study settings;
• became menopausal;
• were sterilised;
• who died;
• whose husbands died.
Sample size: 60,294.
Interventions 7000 ug of retinol equivalent as retinyl palmitate, 42 mg of all-trans beta-carotene or
placebo
Outcomes Primary outcome: all-cause mortality of women related to pregnancy, stillbirth, and
infant mortality up to 12 weeks (84 days) following pregnancy outcome
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West 2011 (Continued)
Notes Vitamin A levels were not measured before starting supplementation
Country: Bangladesh.
Duration: 2001-2007 termed the JiVitA-1 trial.
Study setting: 596 sectors in the rural northwestern district of Gaibandha and Rangpur
between 2001 and 2007
Christian 2013 is a follow-up study of this trials that describes secondary outcomes of
interest (low birthweight and preterm birth) in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “cluster randomization” “sectors were ran-
domized in blocks of nine, to one of three
codes - 1,2,3.”
“field supervisor [were engaged] to in the
process of randomization to increase the
transparency of sector allocation.”
Allocation concealment (selection bias) Low risk “three sets of 3 identical coins on which
the numbers 1, 2 or 3 were written were
placed into a container,mixed and removed
randomly, without replacement and the 3
digit code of each sector was read aloud
sequentially.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “study participants, interviewers, field
supervisors, and investigators remained
masked to treatment assignments until the
end of the trial.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “study participants, interviewers, field
supervisors, and investigators remained
masked to treatment assignments until the
end of the trial.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss of participants < 5%, except for out-
come of low birthweight, which was only
measured for less than 36%
Selective reporting (reporting bias) Low risk Nil reported in the protocol.
Other bias Low risk No other bias awarded.
ANC: antenatal clinic
CRP: C-reactive protein
Hb: haemoglobin
IU: international unit
56Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
LMP: last menstrual period
RCT: randomised controlled trial
RE: retinol equivalents
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alam 2010 The intervention did not include vitamin A.
Banerjee 2009 Intervention uses lycopene which is a compound that lacks beta-ion ring (in the β-carotene), so lycopene cannot
form vitamin A and its biological effects are due to mechanism other than forming vitamin A
Chawla 1995 Not a randomised trial.
Chikobvu 2001 Double-blind randomised trial with outcomes on HIV transmission and HIV complications, only abstract avail-
able
Christian 2003 Cluster-randomised trial with all arms of intervention containing vitamin A and no comparison for vitamin A
Darboe 2007 Intervention started after delivery.
Haskell 2005 Both arms of intervention containing vitamin A and no comparison for vitamin A
Howells 1986 Not a randomised trial.
Humphrey 2006 Intervention started after delivery.
Laitinen 2009 Not a randomised trial and vitamin A present in both arms of intervention
Lietz 2001 Both arms of intervention containing vitamin A and no comparison for vitamin A
Roberfroid 2010 Both arms of intervention containing iron and folic acid and no comparison for vitamin A
Roy 1997 Intervention started after delivery.
Sharma 2003 Intervention uses lycopene which is a compound that lacks beta-ion ring (in the β-carotene), so lycopene cannot
form vitamin A and its biological effects are due to mechanism other than forming vitamin A
Van Vliet 2001 Participants are non-pregnant women.
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Characteristics of ongoing studies [ordered by study ID]
Ahmad 2009
Trial name or title Vitamin A and maternal-infant flu vaccine response
Methods Placebo-controlled double-masked and randomised trial.
Participants Inclusion criteria:
• female 22-35 years;
• mothers at the beginning of second trimester ~ 12 weeks’ gestation;
• willing to stay in Dhaka during pregnancy and willing to admit in the clinic at delivery.
Exclusion criteria:
• history of systemic disease;
• previous complicated pregnancies or of a preterm delivery;
• abortion;
• congenital anomaly;
• hypersensitivity to influenza vaccine or receipt of the vaccine.
Interventions Weekly 10,000 IU vitamin A or placebo.
Outcomes Main outcomes: IgG cord blood plasma; vitamin A cord blood; plasma influenza IgG; colostrum vitamin A;
colostrum influenza sIgA
Other outcomes:
• mothers (6 months postpartum) serum vitamin A;
• serum influ IgG;
• breast milk vitamin A;
• Influ sIgA;
• infants (6 months) anthropometry;
• serum vitamin A;
• serum influ IgG;
• nasal Influ sIgA.
Starting date February 2009.
Contact information International Centre for Diarrhoeal Disease Research, Bangladesh
Notes 66 women randomised.
Setting: Dhaka, Bangladesh.
3 urban maternity clinics.
2010 - no results reported.
IgG: immunoglobulin G
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin A alone versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 4 Risk Ratio (Random, 95% CI) 0.88 [0.65, 1.20]
2 Perinatal mortality 1 Risk Ratio (Fixed, 95% CI) 1.01 [0.95, 1.07]
3 Neonatal mortality 3 Risk Ratio (Fixed, 95% CI) 0.97 [0.90, 1.05]
4 Stillbirth 2 122850 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.10]
5 Maternal anaemia 3 Risk Ratio (Random, 95% CI) 0.64 [0.43, 0.94]
6 Maternal clinical infection 5 Risk Ratio (Random, 95% CI) 0.45 [0.20, 0.99]
7 Maternal night blindness 2 Risk Ratio (Random, 95% CI) 0.79 [0.64, 0.98]
8 Preterm birth 5 40137 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.94, 1.01]
9 Neonatal anaemia 1 406 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.92, 1.08]
10 Neonatal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Congenital malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Low birthweight 4 14599 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.89, 1.16]
Comparison 2. Vitamin A alone versus micronutrient supplement without vitamin A
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Perinatal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Neonatal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Stillbirth 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Maternal anaemia 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Maternal clinical infection 2 591 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.83, 1.18]
7 Maternal night blindness 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Preterm birth 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Neonatal anaemia 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Neonatal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Congenital malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Low birthweight 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Perinatal mortality 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
3 Neonatal mortality 1 594 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.32, 1.31]
4 Stillbirth 2 866 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.57, 3.47]
5 Maternal anaemia 3 706 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.68, 1.09]
6 Maternal clinical infection 2 597 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.80, 1.13]
7 Maternal night blindness 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Preterm birth 1 136 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.08, 1.93]
9 Neonatal anaemia 2 1052 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.38, 1.51]
10 Neonatal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Congenital malformations 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.04, 3.18]
12 Low birthweight 1 594 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.47, 0.96]
Comparison 4. Vitamin A alone versus placebo or no treatment (subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality (infant
mortality level)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
1.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Countries with high infant
mortality
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
2 Maternal mortality (infant
mortality level)
4 Risk Ratio (Random, 95% CI) 0.88 [0.65, 1.20]
2.1 Countries with low infant
mortality
1 Risk Ratio (Random, 95% CI) 0.33 [0.01, 9.44]
2.2 Countries with high infant
mortality
3 Risk Ratio (Random, 95% CI) 0.89 [0.64, 1.23]
3 Maternal mortality (maternal
mortality level)
4 161240 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.76, 1.08]
3.1 Countries with low
maternal mortality
1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
3.2 Countries with high
maternal mortality
3 160690 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.76, 1.08]
4 Perinatal mortality (maternal
mortality level)
1 73743 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.88, 1.03]
4.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Countries with high
maternal mortality
1 73743 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.88, 1.03]
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5 Maternal mortality (prevalence
of vitamin A deficiency)
4 161240 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.20]
5.1 Low prevalence of vitamin
A deficiency
1 550 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.15]
5.2 High prevalence of
vitamin A deficiency
3 160690 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.63, 1.23]
6 Perinatal mortality (prevalence
of vitamin A deficiency)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
6.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 High prevalence of
vitamin A deficiency
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
7 Maternal mortality (prevalence
of HIV in the general
population)
4 161240 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.20]
7.1 Countries with low HIV
prevalence
4 161240 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.20]
7.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Perinatal mortality (prevalence of
HIV in the general population)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
8.1 Countries with low HIV
prevalence
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
8.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Maternal mortality (dose) 3 160690 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.63, 1.23]
9.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Others 3 160690 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.63, 1.23]
10 Perinatal mortality (dose) 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
10.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Others 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
11 Maternal mortality (regimen) 4 161240 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.20]
11.1 Daily 1 550 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.15]
11.2 Weekly 3 160690 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.63, 1.23]
11.3 Other regimen 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Perinatal mortality (regimen) 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
12.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 Weekly 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
12.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Maternal mortality (duration
of intervention)
2 60216 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.82, 1.64]
13.1 One month or less 1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
13.2 More than one month 1 59666 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.83, 1.68]
14 Perinatal mortality (duration of
intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Maternal mortality (trimester
of pregnancy)
4 161240 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.64, 1.20]
15.1 Pre-pregnancy 2 101024 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.50, 1.17]
15.2 First trimester 1 59666 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.83, 1.68]
15.3 Second trimester 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
15.4 Third trimester 1 550 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.15]
61Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15.5 Mixed 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16 Perinatal mortality (trimester
of pregnancy)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
16.1 Pre-pregnancy 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
16.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Maternal mortality
(randomisation)
3 160690 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.63, 1.23]
17.1 Cluster-randomised 3 160690 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.63, 1.23]
17.2 Individual-randomised 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 Perinatal mortality
(randomisation)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
18.1 Cluster-randomised 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
18.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Vitamin A alone versus micronutrient supplement without vitamin A (subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality (infant
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Countries with high infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Perinatal mortality (infant
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Countries with high infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality (maternal
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Countries with high
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Perinatal mortality (maternal
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Countries with high
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Maternal mortality (prevalence
of vitamin A deficiency)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 High prevalence of
vitamin A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Perinatal mortality (prevalence
of vitamin A deficiency)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 High prevalence of
vitamin A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Maternal mortality (prevalence
of HIV in the general
population)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 Countries with low HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Perinatal mortality (prevalence of
HIV in the general population)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.1 Countries with low HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Maternal mortality (dose) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Others 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Perinatal mortality (dose) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Others 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Maternal mortality (regimen) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Perinatal mortality (regimen) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Maternal mortality (duration
of intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal mortality (duration of
intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Maternal mortality (trimester
of pregnancy)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Perinatal mortality (trimester
of pregnancy)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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16.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Maternal mortality
(randomisation)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Perinatal mortality
(randomisation)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
(subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality (infant
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Countries with high infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Perinatal mortality (infant
mortality level)
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
2.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Countries with high infant
mortality
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
3 Maternal mortality (maternal
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Countries with high
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Perinatal mortality (maternal
mortality level)
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
4.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Countries with high
maternal mortality
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
5 Maternal mortality (prevalence
of vitamin A deficiency)
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
5.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.2 High prevalence of
vitamin A deficiency
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
6 Perinatal mortality (prevalence
of vitamin A deficiency)
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
6.1 Low prevalence of vitamin
A deficiency
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
6.2 High prevalence of
vitamin A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Maternal mortality (prevalence
of HIV in the general
population)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 Countries with low HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Perinatal mortality (prevalence of
HIV in the general population)
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
8.1 Countries with low HIV
prevalence
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
8.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Maternal mortality (dose) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Others 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Perinatal mortality (dose) 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
10.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Others 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
11 Maternal mortality (regimen) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Perinatal mortality (regimen) 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
12.1 Daily 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
12.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Maternal mortality (duration
of intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Perinatal mortality (duration of
intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Maternal mortality (trimester
of pregnancy)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Perinatal mortality (trimester
of pregnancy)
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
16.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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16.5 Mixed 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
17 Maternal mortality
(randomisation)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Perinatal mortality
(randomisation)
1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
18.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 Individual-randomised 1 179 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.10, 2.69]
Analysis 1.1. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 1 Maternal
mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 1 Maternal mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Green 1931 -1.10866 (1.711246) 0.8 % 0.33 [ 0.01, 9.44 ]
Kirkwood 2010 -0.08338 (0.120335) 41.5 % 0.92 [ 0.73, 1.16 ]
West 1999 -0.51083 (0.221012) 26.0 % 0.60 [ 0.39, 0.93 ]
West 2011 0.1655 (0.1795) 31.7 % 1.18 [ 0.83, 1.68 ]
Total (95% CI) 100.0 % 0.88 [ 0.65, 1.20 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.01, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 2 Perinatal
mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 2 Perinatal mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Kirkwood 2010 0.00995 (0.030345) 100.0 % 1.01 [ 0.95, 1.07 ]
Total (95% CI) 100.0 % 1.01 [ 0.95, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Vitamin A alone Placebo
Analysis 1.3. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 3 Neonatal
mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 3 Neonatal mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Coutsoudis 1999 -0.34249 (0.474682) 0.7 % 0.71 [ 0.28, 1.80 ]
Kirkwood 2010 -0.05129 (0.043067) 81.0 % 0.95 [ 0.87, 1.03 ]
West 1999 0.09531 (0.090425) 18.4 % 1.10 [ 0.92, 1.31 ]
Total (95% CI) 100.0 % 0.97 [ 0.90, 1.05 ]
Heterogeneity: Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 4 Stillbirth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 4 Stillbirth
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kirkwood 2010 1249/39512 1175/39323 55.7 % 1.06 [ 0.98, 1.14 ]
West 2011 1431/29347 703/14668 44.3 % 1.02 [ 0.93, 1.11 ]
Total (95% CI) 68859 53991 100.0 % 1.04 [ 0.98, 1.10 ]
Total events: 2680 (Vit A), 1878 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 5 Maternal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 5 Maternal anaemia
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Fawzi 1998 -0.17435 (0.255778) 27.7 % 0.84 [ 0.51, 1.39 ]
Suharno 1993 -0.96758 (0.261069) 27.2 % 0.38 [ 0.23, 0.63 ]
West 1999 -0.31471 (0.090425) 45.2 % 0.73 [ 0.61, 0.87 ]
Total (95% CI) 100.0 % 0.64 [ 0.43, 0.94 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 6.19, df = 2 (P = 0.05); I2 =68%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 6 Maternal clinical
infection.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 6 Maternal clinical infection
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Coutsoudis 1999 -0.56212 (0.748015) 14.4 % 0.57 [ 0.13, 2.47 ]
Fawzi 1998 0.1986 (0.1011) 27.6 % 1.22 [ 1.00, 1.49 ]
Green 1931 -0.77653 (0.200388) 26.3 % 0.46 [ 0.31, 0.68 ]
Hakimi 1999 -1.5702 (0.6172) 17.1 % 0.21 [ 0.06, 0.70 ]
West 1999 -2.12026 (0.735802) 14.7 % 0.12 [ 0.03, 0.51 ]
Total (95% CI) 100.0 % 0.45 [ 0.20, 0.99 ]
Heterogeneity: Tau2 = 0.59; Chi2 = 33.59, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 7 Maternal night
blindness.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 7 Maternal night blindness
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
West 1999 -0.35677 (0.078366) 44.3 % 0.70 [ 0.60, 0.82 ]
West 2011 -0.1391 (0.028) 55.7 % 0.87 [ 0.82, 0.92 ]
Total (95% CI) 100.0 % 0.79 [ 0.64, 0.98 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.84, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 8 Preterm birth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 8 Preterm birth
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Coutsoudis 1999 38/335 57/326 1.3 % 0.65 [ 0.44, 0.95 ]
Green 1931 1/275 0/275 0.0 % 3.00 [ 0.12, 73.32 ]
Radhika 2003 9/64 11/58 0.3 % 0.74 [ 0.33, 1.66 ]
van den Broek 2006 29/401 13/203 0.4 % 1.13 [ 0.60, 2.12 ]
West 2011 6474/25487 3293/12713 98.1 % 0.98 [ 0.95, 1.02 ]
Total (95% CI) 26562 13575 100.0 % 0.98 [ 0.94, 1.01 ]
Total events: 6551 (Vit A), 3374 (Placebo or no treatment)
Heterogeneity: Chi2 = 5.60, df = 4 (P = 0.23); I2 =29%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 9 Neonatal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 9 Neonatal anaemia
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fawzi 1998 177/209 168/197 100.0 % 0.99 [ 0.92, 1.08 ]
Total (95% CI) 209 197 100.0 % 0.99 [ 0.92, 1.08 ]
Total events: 177 (Vit A), 168 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 12 Low
birthweight.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 12 Low birthweight
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Coutsoudis 1999 42/346 48/343 10.0 % 0.87 [ 0.59, 1.28 ]
Cox 2005 11/41 5/38 1.8 % 2.04 [ 0.78, 5.33 ]
Radhika 2003 10/64 12/58 2.8 % 0.76 [ 0.35, 1.62 ]
West 2011 4147/9129 2020/4580 85.5 % 1.03 [ 0.99, 1.07 ]
Total (95% CI) 9580 5019 100.0 % 1.02 [ 0.89, 1.16 ]
Total events: 4210 (Vit A), 2085 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.34, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Vitamin A alone versus micronutrient supplement without vitamin A,
Outcome 6 Maternal clinical infection.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 2 Vitamin A alone versus micronutrient supplement without vitamin A
Outcome: 6 Maternal clinical infection
Study or subgroup Vit A
micronutrient
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fawzi 1998 100/165 106/175 96.2 % 1.00 [ 0.84, 1.19 ]
Hakimi 1999 3/128 4/123 3.8 % 0.72 [ 0.16, 3.15 ]
Total (95% CI) 293 298 100.0 % 0.99 [ 0.83, 1.18 ]
Total events: 103 (Vit A), 110 (micronutrient without A)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 2 Perinatal mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 2 Perinatal mortality
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 3 Neonatal mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 3 Neonatal mortality
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kumwenda 2002 12/285 20/309 100.0 % 0.65 [ 0.32, 1.31 ]
Total (95% CI) 285 309 100.0 % 0.65 [ 0.32, 1.31 ]
Total events: 12 (Vit A with micronutrients), 20 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 4 Stillbirth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 4 Stillbirth
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kumwenda 2002 8/306 6/317 74.6 % 1.38 [ 0.48, 3.93 ]
Muslimatun 2001 3/122 2/121 25.4 % 1.49 [ 0.25, 8.75 ]
Total (95% CI) 428 438 100.0 % 1.41 [ 0.57, 3.47 ]
Total events: 11 (Vit A with micronutrients), 8 (micronutrients without A)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 5 Maternal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 5 Maternal anaemia
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fawzi 1998 32/226 31/228 32.1 % 1.04 [ 0.66, 1.65 ]
Muslimatun 2001 36/71 44/66 47.4 % 0.76 [ 0.57, 1.01 ]
Semba 2001 18/63 18/52 20.5 % 0.83 [ 0.48, 1.42 ]
Total (95% CI) 360 346 100.0 % 0.86 [ 0.68, 1.09 ]
Total events: 86 (Vit A with micronutrients), 93 (micronutrients without A)
Heterogeneity: Chi2 = 1.43, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 6 Maternal clinical infection.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 6 Maternal clinical infection
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fawzi 1998 104/173 106/175 92.2 % 0.99 [ 0.84, 1.18 ]
Hakimi 1999 4/123 9/126 7.8 % 0.46 [ 0.14, 1.44 ]
Total (95% CI) 296 301 100.0 % 0.95 [ 0.80, 1.13 ]
Total events: 108 (Vit A with micronutrients), 115 (micronutrients without A)
Heterogeneity: Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 8 Preterm birth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 8 Preterm birth
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dijkhuizen 2004 2/69 5/67 100.0 % 0.39 [ 0.08, 1.93 ]
Total (95% CI) 69 67 100.0 % 0.39 [ 0.08, 1.93 ]
Total events: 2 (Vit A with micronutrients), 5 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 9 Neonatal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 9 Neonatal anaemia
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fawzi 1998 185/219 182/211 51.4 % 0.98 [ 0.91, 1.06 ]
Kumwenda 2002 69/297 132/325 48.6 % 0.57 [ 0.45, 0.73 ]
Total (95% CI) 516 536 100.0 % 0.75 [ 0.38, 1.51 ]
Total events: 254 (Vit A with micronutrients), 314 (micronutrients without A)
Heterogeneity: Tau2 = 0.24; Chi2 = 29.31, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 11 Congenital malformations.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 11 Congenital malformations
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dijkhuizen 2004 1/89 3/90 100.0 % 0.34 [ 0.04, 3.18 ]
Total (95% CI) 89 90 100.0 % 0.34 [ 0.04, 3.18 ]
Total events: 1 (Vit A with micronutrients), 3 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 12 Low birthweight.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 12 Low birthweight
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kumwenda 2002 40/285 65/309 100.0 % 0.67 [ 0.47, 0.96 ]
Total (95% CI) 285 309 100.0 % 0.67 [ 0.47, 0.96 ]
Total events: 40 (Vit A with micronutrients), 65 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 1
Perinatal mortality (infant mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 1 Perinatal mortality (infant mortality level)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low infant mortality
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Countries with high infant mortality
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 2
Maternal mortality (infant mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 2 Maternal mortality (infant mortality level)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Countries with low infant mortality
Green 1931 -1.10866 (1.711246) 0.8 % 0.33 [ 0.01, 9.44 ]
Subtotal (95% CI) 0.8 % 0.33 [ 0.01, 9.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 Countries with high infant mortality
Kirkwood 2010 -0.08338 (0.120335) 41.5 % 0.92 [ 0.73, 1.16 ]
West 1999 -0.51083 (0.221012) 26.0 % 0.60 [ 0.39, 0.93 ]
West 2011 0.1655 (0.1795) 31.7 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 99.2 % 0.89 [ 0.64, 1.23 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 5.65, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 100.0 % 0.88 [ 0.65, 1.20 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.01, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.56), I2 =0.0%
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Analysis 4.3. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 3
Maternal mortality (maternal mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 3 Maternal mortality (maternal mortality level)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low maternal mortality
Green 1931 0/275 1/275 0.6 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.6 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Countries with high maternal mortality
Kirkwood 2010 138/39601 148/39234 55.7 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 21.7 % 0.60 [ 0.40, 0.89 ]
West 2011 104/39804 44/19862 22.0 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 94353 66337 99.4 % 0.91 [ 0.76, 1.08 ]
Total events: 295 (Vit A), 235 (Placebo or no treatment)
Heterogeneity: Chi2 = 6.34, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 94628 66612 100.0 % 0.91 [ 0.76, 1.08 ]
Total events: 295 (Vit A), 236 (Placebo or no treatment)
Heterogeneity: Chi2 = 6.71, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 4.4. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 4
Perinatal mortality (maternal mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 4 Perinatal mortality (maternal mortality level)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low maternal mortality
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Countries with high maternal mortality
Kirkwood 2010 1140/37042 1187/36701 100.0 % 0.95 [ 0.88, 1.03 ]
Subtotal (95% CI) 37042 36701 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 1140 (Vit A), 1187 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 37042 36701 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 1140 (Vit A), 1187 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 5
Maternal mortality (prevalence of vitamin A deficiency).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 5 Maternal mortality (prevalence of vitamin A deficiency)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low prevalence of vitamin A deficiency
Green 1931 0/275 1/275 0.9 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.9 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 High prevalence of vitamin A deficiency
Kirkwood 2010 138/39601 148/39234 40.1 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.9 % 0.60 [ 0.40, 0.89 ]
West 2011 104/39804 44/19862 31.1 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 94353 66337 99.1 % 0.88 [ 0.63, 1.23 ]
Total events: 295 (Vit A), 235 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.34, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 94628 66612 100.0 % 0.87 [ 0.64, 1.20 ]
Total events: 295 (Vit A), 236 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.71, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
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Analysis 4.6. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 6
Perinatal mortality (prevalence of vitamin A deficiency).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 6 Perinatal mortality (prevalence of vitamin A deficiency)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low prevalence of vitamin A deficiency
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High prevalence of vitamin A deficiency
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 7
Maternal mortality (prevalence of HIV in the general population).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 7 Maternal mortality (prevalence of HIV in the general population)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Countries with low HIV prevalence
Green 1931 0/275 1/275 0.9 % 0.33 [ 0.01, 8.15 ]
Kirkwood 2010 138/39601 148/39234 40.1 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.9 % 0.60 [ 0.40, 0.89 ]
West 2011 104/39804 44/19862 31.1 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 94628 66612 100.0 % 0.87 [ 0.64, 1.20 ]
Total events: 295 (Vit A), 236 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.71, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Countries with high HIV prevalence
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 94628 66612 100.0 % 0.87 [ 0.64, 1.20 ]
Total events: 295 (Vit A), 236 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.71, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 8
Perinatal mortality (prevalence of HIV in the general population).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 8 Perinatal mortality (prevalence of HIV in the general population)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low HIV prevalence
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 Countries with high HIV prevalence
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 9
Maternal mortality (dose).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 9 Maternal mortality (dose)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Daily 10,000 IU
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Others
Kirkwood 2010 138/39601 148/39234 39.7 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 28.6 % 0.60 [ 0.40, 0.89 ]
West 2011 104/39804 44/19862 31.7 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 94353 66337 100.0 % 0.88 [ 0.63, 1.23 ]
Total events: 295 (Vit A), 235 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.34, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 94353 66337 100.0 % 0.88 [ 0.63, 1.23 ]
Total events: 295 (Vit A), 235 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.34, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 10
Perinatal mortality (dose).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 10 Perinatal mortality (dose)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily 10,000 IU
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Others
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 11
Maternal mortality (regimen).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 11 Maternal mortality (regimen)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Daily
Green 1931 0/275 1/275 0.9 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.9 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Weekly
Kirkwood 2010 138/39601 148/39234 40.1 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.9 % 0.60 [ 0.40, 0.89 ]
West 2011 104/39804 44/19862 31.1 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 94353 66337 99.1 % 0.88 [ 0.63, 1.23 ]
Total events: 295 (Vit A), 235 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.34, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.75 (P = 0.45)
3 Other regimen
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 94628 66612 100.0 % 0.87 [ 0.64, 1.20 ]
Total events: 295 (Vit A), 236 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.71, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
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Analysis 4.12. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 12
Perinatal mortality (regimen).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 12 Perinatal mortality (regimen)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Weekly
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
3 Other regimen
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 13
Maternal mortality (duration of intervention).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 13 Maternal mortality (duration of intervention)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 One month or less
Green 1931 0/275 1/275 2.5 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 2.5 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 More than one month
West 2011 104/39804 44/19862 97.5 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 39804 19862 97.5 % 1.18 [ 0.83, 1.68 ]
Total events: 104 (Vit A), 44 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI) 40079 20137 100.0 % 1.16 [ 0.82, 1.64 ]
Total events: 104 (Vit A), 45 (Placebo or no treatment)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
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Analysis 4.15. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 15
Maternal mortality (trimester of pregnancy).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 15 Maternal mortality (trimester of pregnancy)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pre-pregnancy
Kirkwood 2010 138/39601 148/39234 40.1 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.9 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54549 46475 67.9 % 0.77 [ 0.50, 1.17 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.23 (P = 0.22)
2 First trimester
West 2011 104/39804 44/19862 31.1 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 39804 19862 31.1 % 1.18 [ 0.83, 1.68 ]
Total events: 104 (Vit A), 44 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 Second trimester
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Third trimester
Green 1931 0/275 1/275 0.9 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.9 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
5 Mixed
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 94628 66612 100.0 % 0.87 [ 0.64, 1.20 ]
Total events: 295 (Vit A), 236 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.71, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 2.79, df = 2 (P = 0.25), I2 =28%
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Analysis 4.16. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 16
Perinatal mortality (trimester of pregnancy).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 16 Perinatal mortality (trimester of pregnancy)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-pregnancy
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 First trimester
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Second trimester
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Third trimester
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Mixed
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 4.17. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 17
Maternal mortality (randomisation).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 17 Maternal mortality (randomisation)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cluster-randomised
Kirkwood 2010 138/39601 148/39234 39.7 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 28.6 % 0.60 [ 0.40, 0.89 ]
West 2011 104/39804 44/19862 31.7 % 1.18 [ 0.83, 1.68 ]
Subtotal (95% CI) 94353 66337 100.0 % 0.88 [ 0.63, 1.23 ]
Total events: 295 (Vit A), 235 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.34, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Individual-randomised
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 94353 66337 100.0 % 0.88 [ 0.63, 1.23 ]
Total events: 295 (Vit A), 235 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.34, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 4.18. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 18
Perinatal mortality (randomisation).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 18 Perinatal mortality (randomisation)
Study or subgroup Vit A
Placebo or
no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cluster-randomised
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 Individual-randomised
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 2 Perinatal mortality (infant mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 2 Perinatal mortality (infant mortality level)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low infant mortality
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Countries with high infant mortality
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 4 Perinatal mortality (maternal mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 4 Perinatal mortality (maternal mortality level)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low maternal mortality
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Countries with high maternal mortality
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin A Favours micronutrients
99Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.5. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 5 Maternal mortality (prevalence of vitamin A deficiency).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 5 Maternal mortality (prevalence of vitamin A deficiency)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low prevalence of vitamin A deficiency
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High prevalence of vitamin A deficiency
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 6 Perinatal mortality (prevalence of vitamin A deficiency).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 6 Perinatal mortality (prevalence of vitamin A deficiency)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low prevalence of vitamin A deficiency
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
2 High prevalence of vitamin A deficiency
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 8 Perinatal mortality (prevalence of HIV in the general population).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 8 Perinatal mortality (prevalence of HIV in the general population)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low HIV prevalence
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
2 Countries with high HIV prevalence
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.10. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 10 Perinatal mortality (dose).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 10 Perinatal mortality (dose)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily 10,000 IU
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Others
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.12. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 12 Perinatal mortality (regimen).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 12 Perinatal mortality (regimen)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
2 Weekly
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Other regimen
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.16. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 16 Perinatal mortality (trimester of pregnancy).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 16 Perinatal mortality (trimester of pregnancy)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-pregnancy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 First trimester
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Second trimester
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Third trimester
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Mixed
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 6.18. Comparison 6 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A (subgroups), Outcome 18 Perinatal mortality (randomisation).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 6 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A (subgroups)
Outcome: 18 Perinatal mortality (randomisation)
Study or subgroup
Vit A with
micronutri-
ents
micronutrients
without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cluster-randomised
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vit A with micronutrients), 0 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Individual-randomised
Dijkhuizen 2004 2/89 4/90 100.0 % 0.51 [ 0.10, 2.69 ]
Subtotal (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 89 90 100.0 % 0.51 [ 0.10, 2.69 ]
Total events: 2 (Vit A with micronutrients), 4 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Retinol supplementation to vitamin A conversion table
Retinol supplementation in mcg Vitamin A in IU
1 3.33
2 6.66
3 9.99
IU: international units
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Table 2. Serum retinol conversion table
Serum retinol mcg/dL Serum retinol mc mol/L
10 0.35
20 0.7
30 1.05
WH A T ’ S N E W
Last assessed as up-to-date: 30 March 2015.
Date Event Description
30 March 2015 New search has been performed Search updated. Methods updated. ’Summary of find-
ings’ tables have been incorporated for this update
30 March 2015 New citation required but conclusions have not changed Three new studies have been included in this update
(Hakimi 1999; Sun 2010; West 2011). The review now
includes a total of 19 studies. The conclusions remain
the same
H I S T O R Y
Protocol first published: Issue 9, 2010
Review first published: Issue 11, 2010
Date Event Description
15 February 2011 Amended Authors of the Kirkwood 2010 trial provided additional information about the loss to follow up
figure for the pregnancy-related mortality analysis, which was 8% and not 44%
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Methods updated to current standard text of Cochrane Pregnancy and Childbirth. ’Summary of findings’ tables have been incorporated
for the 2015 update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anemia [prevention & control]; Infant Mortality; Maternal Mortality; Night Blindness [drug therapy]; Pregnancy Complications
[∗drug therapy]; Pregnancy Complications, Infectious [drug therapy]; Vitamin A [∗administration & dosage]; Vitamin A Deficiency
[∗drug therapy]; Vitamins [∗administration & dosage]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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